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The case of andrew speaker 
In May 2007, Andrew Speaker hit the headlines when he took two transatlantic flights 
while presumably having extensively drug-resistant tuberculosis (XDR-TB).1 He had been 
diagnosed with multidrug-resistant tuberculosis (MDR-TB) two weeks before and had been 
advised by local health authorities not to travel. Speaker flew from Atlanta to Paris anyway 
and on to Greece and then to Italy for his honeymoon. On May 22, the Centers for Disease 
Control and Prevention (CDC) thought he had XDR-TB (it later turned out this was incorrect 
and Speaker had MDR-TB instead) and issued a notice to Speaker that travel would be against 
medical advice and that he should report to local health authorities. Instead, Speaker took a 
flight from Italy to Prague, then to Montreal and drove into the United States, where he was 
ultimately placed under involuntary isolation in a US hospital. Upon his return to the US, the 
CDC issued an international alarm asking airline passengers and cabin personnel from the two 
transatlantic flights to be tested for TB.2 This was quickly picked up by international media, 
creating an international scare for a deadly bug spreading across Europe.3  
The history of drug-resistant tuberculosis 
This scare of a patient with drug-resistant tuberculosis travelling through Europe proved to be 
a reality check on the way we looked at (multi)drug-resistant tuberculosis.1 Once the world’s 
most important cause of death, global tuberculosis incidence and case fatality rates fell thanks 
to the use of a standardised combination of different antituberculosis drugs under directly 
observed therapy (DOTS). These first-line antituberculosis drugs are rifampicin, isoniazid, 
pyrazinamide and ethambutol. Treatment success rates of drug-susceptible TB have steadily 
improved and cure rates reached their highest level of 87% in 2009.4 These advances in 
antituberculosis therapy led to the widespread believe that TB had been conquered and TB was 
a disease of the past.5 As TB cases dropped in wealthy countries, funding for research dried 
up and TB programs were cut by governments.6,7 In the resource-limited countries, national 
TB programs kept on relying on microscopy as the basis for case detection and the treatment 
approach was based on the empirical use of first-line drugs.7 
Within these settings drug-resistant tuberculosis emerged. By the 1990s, the city of New York 
saw a foretaste of the TB threat the world was awaiting.6 A sharp rise of MDR-TB cases, i.e. 
M. tuberculosis complex strains resistant to the two most effective first-line drugs rifampicin 
and isoniazid, was seen in New York City in the beginning of the 1990s.8 These notifications 
exceeded those of many low-income countries in some parts of the city and by 1991 New York 
City accounted for a remarkable 61% of all cases of MDR-TB in the United States.6 Public health 
care officials developed a plan to combat this MDR-TB epidemic which consisted of proper 
infection control methods, improved diagnostic laboratory methods, and directly observed 
therapy with at least four effective drugs.6 As a result, new cases decreased substantially 
within two years. The New York experience offered a blueprint for combating the MDR-TB 
threat globally, yet it was not taken up by international policy makers at that time.7 Treating 
MDR-TB was thought to be too expensive and complex.7 Moreover, a focus on treating MDR-
TB would distract attention from the highly cost-effective DOTS strategy.7 Drug susceptibility 
testing was not widely advocated because it was thought that the long turn-around-time and 
subjective readings of tests on solid medium were insufficient to guide treatment decisions.9 
As a consequence, new antituberculosis drugs, such as fluoroquinolones, were added to failing 
TB regimens without a concomitant upscale in laboratory diagnostic services.7
And by 2005, physicians treating multidrug-resistant tuberculosis were faced with an even 
bigger threat, extensively drug-resistant tuberculosis (XDR-TB). This form of tuberculosis 
is caused by strains of Mycobacterium tuberculosis complex that are not only resistant 
to rifampicin and isoniazid, but also to fluoroquinolones and second-line injectables 
(capreomycin, amikacin, kanamycin). Outbreaks of XDR-TB reporting high mortality rates 
in South Africa10 finally resulted in the highly needed changes in the way TB programs were 
organised. Since then, strategies such as the strengthening of health care services, the rollout of 
new technologies for detecting drug-resistant tuberculosis and the improved access to drugs 
have resulted in declining trends of MDR-TB in some regions of the world.4,11 
Current challenges to global tuberculosis control 
Today, MDR-TB and XDR-TB remain a threat to global tuberculosis control. In their 2012 
global report, the WHO has estimated that approximately 4% of new TB cases and 20% of 
previously treated TB cases are diagnosed with MDR-TB.4 XDR-TB is seen in 9% of all MDR-
TB notifications and the number of countries reporting XDR-TB cases is increasing. The MDR-
TB notifications are often alarmingly high in countries of the former Soviet Union. In Minsk, 
Belarus, for example, MDR-TB is diagnosed in 35% of new cases and in 77% of previously 
treated cases.12 
A major barrier for global TB control has been the lack of access to accurate tests for diagnosing 
MDR-TB and XDR-TB.13 First-line drug susceptibility testing (DST) is performed in less 
than 4% of new TB cases and 6% of previously treated cases.13 As a consequence, many MDR-
TB cases remain undetected. New technologies based on identifying resistance-associated 
mutations in the DNA of M. tuberculosis complex bacteria may provide results within hours 
and may have the potential to serve as rapid screening tests for drug resistance. The recent 
introduction of the Xpert MTB/RIF assay, detecting both M. tuberculosis as well as mutations 
associated with rifampicin resistance, has been an important step up in improving rapid 
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diagnosis of MDR-TB. It is has been rolled out worldwide and is currently recommended 
as the first diagnostic assay for individuals suspected to have (MDR)-TB in high-burden 
settings.14
A second barrier has been the availability of quality assured antituberculosis drugs once the 
diagnosis of MDR-TB has been made.13 To increase the arsenal of anti-tuberculosis drugs, a lot 
of effort has been put into developing new compounds.15 New drugs effective against MDR-
TB and XDR-TB, such as bedaquiline and delamanid, have passed the first regulatory hurdles 
and have reached the market. Another successful approach has been to repurpose existing 
drugs for tuberculosis treatment, such as linezolid, or to optimize the dose and thus its efficacy 
of existing antituberculosis drugs, such as rifampicin. Next-generation antituberculosis 
regimens are likely to consist of a combination of several of these new and already existing 
drugs. The ultimate goal of these next-generation treatment regimens will be to ensure that all 
patients with drug-resistant tuberculosis can be confident that their regimen will be safe and 
effective.16 
aligning new treatment regimens with drug susceptibility testing 
To be safe and effective, the introduction of next-generation treatment regimens should be 
aligned with drug susceptibility testing (DST).16 Information on DST is essential because it 
can identify patients who will require early adaptation of the standard treatment. DST will 
also prevent patients from taking ineffective but toxic drugs for an extended period, which 
could lead to amplification of drug resistance. On a national level, DST can be used to monitor 
patterns of emerging drug resistance and may help to decide if introducing new treatment 
regimens will be successful. Ultimately, the alignment of DST with new treatment regimens is 
a prerequisite for reversing the global threat of MDR-TB and XDR-TB.
An optimal DST strategy should be sought for each new treatment regimen. Which DST 
strategy is best depends on the prevailing drug resistance level, the selection of patient 
population eligible for testing, and the health-care system implementing the algorithm.16 This 
should be preceded by a thorough understanding of the accuracy and performance of different 
diagnostic strategies, in real-life settings and under varying epidemiological situations. This is 
the main topic of this thesis.
outline of the thesis 
This thesis is divided into two parts. The main part focuses on different strategies for 
optimising the diagnosis of drug-resistant tuberculosis. Chapter 2 introduces the different 
modalities for drug susceptibility testing (DST) in tuberculosis. It describes the history of 
DST from the pivotal article by Canetti in 1963 to the recently developed molecular assays 
such as the Xpert MTB/RIF and the MTBDRsl test. Chapters 3 to 5 address the difficulties 
in detecting pyrazinamide resistance, a first-line antituberculosis drug with increasing 
importance in the treatment of drug-resistant tuberculosis. Caveats in the phenotypic and 
molecular diagnosis of pyrazinamide resistance in both susceptible and multidrug-resistant 
tuberculosis are discussed. Chapters 6 and 7 focus on the accuracy of three DST assays for 
detecting drug-resistant tuberculosis. In chapter 6, we describe the diagnostic accuracy of 
the Genotype® MTBDRsl molecular assay and the MGIT960® liquid culture based method 
for detecting resistance to second-line antituberculosis drugs compared to the Middlebrook 
7H10 agar dilution method. In chapter 7, we report on the performance of the Genotype® 
MTBDRplus and MTBDRsl assay for detecting drug resistance in the Netherlands and discuss 
the role of these molecular tests in low-level drug resistance countries.  
The second part of this thesis focuses on the potential of existing drugs for treating drug-
resistant tuberculosis. The antimycobacterial activity of efflux pump inhibitors is described in 
chapter 8, where we present the in vitro activity of multiple phenothiazines and SILA421, an 
organosilicon compound, against a panel of M. tuberculosis strains with varying susceptibility 
profiles. The antimycobacterial activity of other drug classes is described in chapter 9, where 
we present the in vitro antimycobacterial activity of fusidic acid, nitrofurantoin, mefloquine, 
co-trimoxazole, amoxicillin with clavulanic acid and meropenem with clavulanic acid. 
The results provided within the framework of this thesis should contribute to a better 
understanding of the accuracy and performance of the different diagnostic modalities in 
real-life settings and under different epidemiological settings. This thesis concludes with a 
summary of the main results in chapters 10 and 11, together with a general discussion and 
suggestions for future research in chapter 12.
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Introduction 
Tuberculosis (TB) has brought misery to the world since ancient times.1 It used to be one of 
the major causes of death worldwide with case fatality rates approximating 70%.2 And still 
today the global burden of TB remains enormous. Yearly, around 8,7 million new cases of TB 
are diagnosed and 1,4 million people die of TB.3 With this gloomy view in mind, the euphoria 
caused by the discovery of streptomycin in the early 1940s is not so surprising.4 It marked a 
new era in TB treatment and changed the prognosis from dismal to the expectation of cure.5 
Soon after the discovery of streptomycin, studies noted the occurrence of streptomycin 
resistance during streptomycin monotherapy.6 Importantly, this resistance undermined 
treatment success for TB. Pyle and colleagues made a crucial observation; they showed that M. 
tuberculosis strains isolated from the sputum before treatment were not uniformly susceptible 
to streptomycin.7 Crofton and Mitchinson inferred from these observations that streptomycin 
monotherapy might favour the growth of resistant subpopulations.8 
The origins of drug resistance 
This existence of resistant subpopulations still underlies our current idea on the emergence 
of primary drug resistance in M. tuberculosis. It is thought that all larger populations of 
M. tuberculosis naturally contain mutant subpopulations encoding resistance against all 
antituberculosis drugs and that in drug-resistant M. tuberculosis strains the proportion 
of resistance bacilli is considerably higher than in susceptible strains.9,10 Such resistant 
subpopulations arise through spontaneously occurring mutations and are generally considered 
not to be of clinical importance in wild type M. tuberculosis strains.11,12 It is during drug treatment 
that resistant subpopulations can multiply depending on the selective antibiotic pressure.13 Drug 
concentrations below the minimum inhibitory concentration (MIC) of a mutant subpopulation 
but above the MIC of a susceptible subpopulation favour the growth of the mutant 
subpopulation, thereby selecting for the development of a drug resistant M. tuberculosis strain. 
Whether an M. tuberculosis isolate should be considered as resistant thus depends on the 
proportion of resistant subpopulations for a given concentration of an antituberculosis drug. 
It has been previously defined that a M. tuberculosis strain should be considered susceptible 
if this proportion does not exceed 1% of the total population.10,14 For both pyrazinamide and 
ethambutol this proportion originally was 10%.9,10 It could be determined by testing a M. 
tuberculosis culture against a series of drug concentrations and determining the minimal drug 
concentration inhibiting growth (the MIC).9 Rather, mostly a single cut-off concentration is 
used to determine whether an isolate should be considered to be resistant or not, the so-called 
critical concentration.14,15 Ideally this concentration should lie between the MIC of susceptible 
and resistant strains, but it is mostly derived from a MIC distribution of wild strains of M. 
tuberculosis that have never been exposed to drugs and determined as the concentration 
inhibiting the growth 95% (90% for pyrazinamide) of the wild type strains.10,14,15
Drug susceptibility testing on solid media 
The 1%-rule forms the basis of our current in vitro drug susceptibility testing (DST) and has 
already been laid out in 1963 by Canetti and colleagues.16 They proposed three methods for DST: 
the absolute concentration method, the resistance ratio method, and the proportion method. 
In the absolute concentration method M. tuberculosis bacteria are incubated on media that 
contain various drug concentrations including the critical concentration.16,17 Growth at and above 
the critical concentration is interpreted as resistant. In the resistance ratio method, the MIC is 
divided by the MIC of the M. tuberculosis H37rv reference strain giving a ratio. A ratio of > 2 is 
considered as resistant.17 In the proportion method, multiple standard dilutions of the inoculum 
are used. The number of colonies are then counted on drug containing medium from the most 
diluted inoculum and compared with the number of colonies in on drug free medium.9,17 The 
isolate is considered to be resistant if the number of resistant bacillary units is more than 1% 
(or 10%) at the tested concentration.9,17 Though initially described for DST in the egg-based 
Löwenstein-Jensen agar, the proportion method was later on adjusted to the Middlebrook 7H10 
agar and is still propagated for second-line DST by the World Health Organization.18 
Drug susceptibility testing (DST) did not gain much popularity after its standardization. 
The first argument against the use of DST was that the extended turn-around-time of 6-8 
weeks in the laboratory could not influence treatment decisions in a timely manner.19 The 
second argument against the use of DST was related to the successful use of multiple drugs 
for treatment.19 Because the antituberculosis regimen combining 4-5 drugs was very potent, 
it was thought that this would completely abolish failure and relapse resulting from initial 
drug resistance.20 Together with the low prevalence of drug resistance among M. tuberculosis 
isolates, systematic surveys on drug resistance were not widely advocated. 
Drug susceptibility testing in liquid medium 
In the late 1970s liquid culture methods for DST were developed. In contrast to the earlier 
developed methods in which growth was detected by visual inspection, these liquid culture 
systems could detect growth of M. tuberculosis automatically. One of the first versions of 
this approach (the BacTec460, BD Biosciencem Sparks, Md, USA) utilized a radioactive label 
for the detection of growth.21 MIC determination by liquid culture systems is performed 
by inoculating media with different drug concentrations together with a 1:100 inoculum 
dilution in a drug-free vial.17 Its methodology resembles to proportion method and therefore 
is sometimes referred to as proportion method in liquid media.17 To represent 99% inhibition, 
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the MIC is defined as the lowest drug concentration that yields growth index readings lower 
than those in the drug-free tube.17
Its introduction was a major improvement in turn-around-time for DST in TB: an average of 
18 days was required by the BacTec 460 radiometric method for complete recovery and drug 
susceptibility testing of M. tuberculosis, as compared with 38.5 days for the conventional solid 
medium methods.21 Furthermore, accuracy for detecting resistance to first-line and second-
line antituberculosis drugs was excellent.21,22 The BacTec 460 radiometric method, however, 
had its disadvantages and has largely been abandoned as a tool for drug susceptibility testing. 
Instead, nonradiometric liquid culture systems have been developed, such as the MB/BacT 
system and the Mycobacteria Growth Indicator Tube (MGIT) 960 system. The MGIT is most 
extensively studied and is likely to become the new gold standard.23
Introduced in 1995, the MGIT 960 is a nonradiometric culture system to culture M. 
tuberculosis from clinical specimens and to perform DST.24 The MGIT medium consists of a 
modified Middlebrook 7H9 broth and uses a fluorescent technology to measure mycobacterial 
growth.25 This technology is based on the indirect detection of the oxygen consumption of 
myobacteria in the broth. The initial concentration of oxygen quenches fluorescence, but as 
mycobacterial growth occurs and oxygen is taken up, the lower oxygen concentration permits 
the indicator to fluoresce. This fluorescence is detected using a 365-nm UV transilluminator. 
Drug susceptibility testing in the MGIT was initially set up -and currently almost invariably 
used- as a qualitative system,26 which means only one critical concentration of the drug is 
tested for growth of a clinical M. tuberculosis isolate. Similar to the BacTec 460 system, drug 
susceptibility is measured by comparing fluorescence -and hence growth of M. tuberculosis- 
in drug containing tube with that of a drug-free control tube incubated with a 1:100 diluted 
inoculum. If relative growth in de drug tube is equal or exceeds growth in the control tube, 
the isolate is considered resistant. If the relative growth is less than that in the growth control 
tube, the isolate is considered susceptible. 
In 1999, a multi-centre study was published comparing the DST results of the MGIT 
system against DST results of the BacTec 460 for streptomycin, ethambutol, rifampicin and 
isoniazid.27 The proportion method on solid medium was used as the gold standard in case of 
discordant results. A high agreement rate was observed (98.6%) among the 440 isolates tested. 
The authors concluded that drug susceptibility testing in the MGIT for first line drugs is as 
accurate as the BacTec 460. Recent meta-analyses have confirmed the accuracy and reliability 
of the MGIT 960 system to detect resistance to first-line antituberculosis drugs (Table 1).28,29 
Table 1 
Diagnostic accuracy of the MGIT 960 system to detect resistance to first-line antituberculosis drugsa,b
Drug CCc sensitivity Specificity agreement 
streptomycin 1.0 99.7 (74.3-100) 94.3 (76.7-98.8) 96.4 (94.0-98.9)
Isoniazid 0.1 98.9 (94.4-99.8) 98.2 (95.4-99.3) 98.7 (97.7-99.7)
rifampicin 1.0 98.2 (92.9-99.6) 99.6 (98.5-99.9) 99.5 (98.6-100)
ethambutol 5.0 83.9 (72.7-91.1) 95.8 (80.9-99.2) 95.3 (92.5-98.0)
a Adapted from reference [29] 
b Estimates are given in percentages with 95% confidence interval in brackets 
c CC, critical concentration given in mg/l 
Drug susceptibility testing to pyrazinamide for the MGIT system was introduced in 2002 
by Pfyffer and colleagues.30 Using a modified 7H9 broth with a pH value adjusted to 5.9, the 
MGIT pyrazinamide medium differs slightly of that for other first-line drugs. A review by 
Piersimoni and colleagues has shown that, at the critical concentration of 100 mg/l, sensitivity 
of the MGIT for detecting pyrazinamide resistance was between 96-100% and specificity was 
between 87-100%.28 The lower specificity is caused by higher rates of false positives in the 
MGIT. This was confirmed in a recent study by Chedore and colleagues.31 In their study on 743 
isolates, 57 were found resistant using the MGIT 960. Repeated testing with the BacTec 460 
and Wayne’s assay found that 24 isolates (42%) were in fact pyrazinamide susceptible. 
In 2006, Rusch-Gerdes and colleagues demonstrated that the MGIT could also be used for 
DST to second-line antituberculosis drugs.32 Validation of DST to second-line antituberculosis 
drugs in the MGIT system has been hampered however by differences in methodology 
between the various studies, the lack of standardisation in drug preparation and drug 
concentrations, and the lack of sufficient studies on clinical specimens.29,33 Moreover, definite 
critical concentrations in the MGIT 960 system for most second-line drugs have not been well 
established.29 This is because MICs of resistant and susceptible isolates of many second-line 
drugs are close to each other.34 Also, data on the relationship of critical concentrations and 
clinical outcome are lacking for many second-line drugs.33 As a consequence, DST to second-
line antituberculosis drugs in the MGIT 960 system has not been sufficiently validated and 
standardized.
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Molecular detection of drug resistance  
Primary drug resistance in M. tuberculosis arises via the selection of variants with 
spontaneously occurring mutations.11,13 This mutant selection depends on the available drug 
concentration.13 If these mutations occur in restricted genomic sites, they may be used as a 
surrogate marker for drug resistance. This association between point mutations and drug 
resistance forms the basis for our current molecular DST techniques and has markedly 
fastened the diagnosis of drug resistance.  
Molecular targets for first-line antituberculosis drugs are listed in Table 2. Point mutations in 
the central region of the RNA polymerase beta subunit gene (rpoB), the main binding site for 
rifampicin, are seen in up to 96% of rifampicin resistant isolates.35 Isoniazid resistance is most 
often linked to mutations in the katG gene encoding the catalase-peroxidase enzyme which 
is necessary for isoniazid activation.36 Mutations in this gene are seen in 50-95% of isoniazid 
resistant isolates and are usually associated with high-level resistance.36 Low-level resistance 
is associated with mutations in the promoter region of mabA/inhA operon and occur in 8-43% 
of isoniazid resistance isolates.36 Resistance to the other first-line antituberculosis drugs has 
also been linked to certain target gene sequences, but are less frequently used for molecular 
drug susceptibility so far. Ethambutol resistance has been linked to mutations in the embB 
gene in 47-65% of isolates, and pyrazinamide resistance has been linked to mutations in the 
pyrazinamidase (pncA) gene in 72-95% of isolates.36  
Table 2 
Mutations in the M. tuberculosis gene associated with resistance to first-line antituberculosis drugsa
antituberculosis  
drug
Target gene product frequency among  
drug-resistant isolates
Rifampicin rpoB β subunit of RNA polymerase > 95%
Isoniazid katG Catalase-peroxidase 50-95%
inhA Enoyl-ACP reductase 8-43%
Ethambutol embB Arabinosyltransferases 47-65%
Pyrazinamide pncA Pyrazinamidase 72-95%
a Adapted from reference [11]
The first commercially available molecular techniques have mainly focused on analysing 
the rpoB gene because of its high agreement with phenotypic resistance and because 
rpoB mutations are a good surrogate marker for MDR-TB in high-burden regions.37 Solid-
phase hybridization techniques, or line probe assays (LPA), were one of the first of such 
commercially available molecular assays which were widely deployed. LPAs are based on the 
reverse line blot hybridization of oligonucleotides on paper strips on which specific probes 
with wild type and mutant sequences have been immobilized.38 The target gene sequences in 
the M. tuberculosis gene are amplified, denatured to get them single stranded, and applied to 
the strips with the specific probes. Hybridization is revealed by the development of a coloured 
reaction on the strip.38 
The GenoType MTBDRplus (Hain Lifesciences) assay is an example of such a LPA for the 
diagnosis of rifampicin and isoniazid resistance.39 With this assay mutations are identified in 
the rpoB gene as well as mutations in the katG gene and in the inhA gene. A study in South-
Africa showed that time to diagnosing MDR-TB could be shortened to 2 days by using the 
MTBDRplus assay.40 A recent meta-analysis confirmed that the Genotype MDRTBplus had 
an excellent diagnostic accuracy for direct drug susceptibility testing on clinical samples.41 For 
rifampicin, the pooled sensitivity was 99% (96-100%) and pooled specificity was 99% (95%-
CI: 98%-100%). Direct susceptibility testing for isoniazid yielded similarly results. Pooled 
sensitivity was 96% (95%-CI: 93%-99%) and pooled specificity was 100% (95%-CI: 99%-
100%). 
Given that the GenoType MTBDRplus is a LPA, it suffers from certain drawbacks. LPAs are 
only registered for use on sputum smear-positive specimens and on M. tuberculosis cultures.42 
This is because its applicability in smear-negative sputum samples is relatively poor.43 Other 
drawbacks are its high costs and the requirement for separate clean room facilities to avoid 
contamination of the amplification reaction.44 Nonetheless, recent studies seem to indicate 
that the deployment of an LPA in the diagnosis of rifampicin resistance may be cost-effective 
and applicable in rural areas,45,46 and may even shorten time to diagnosis of MDR-TB by a 
median of 6 weeks.47
Recently, a LPA for the detection of resistance to second-line antituberculosis drugs has 
been developed; the GenoType MTBDRsl assay.48 This test is based on the association 
between fluoroquinolone resistance and mutations in the gyrA gene and the relation between 
mutations in the rrs gene and resistance to second-line injectables. Mutations in the gyrA 
gene for instance have been detected in up to 92% of fluoroquinolone resistant isolates49 and 
mutations in the rrs gene have been detected in up to 85% of amikacin and capreomycin 
resistant isolates.50 The MTBDRsl LPA contains six probes targeting the most common gyrA 
mutations and two probes targeting rrs gene mutations. The MTBDRsl strip also contains 
two probes for detecting mutations in the embB gene that are associated with ethambutol 
resistance. Hillemann and colleagues have tested the Genotype MTBDRsl in 106 clinical 
samples,48 sixty-three isolates of which were multidrug resistant. Overall, sensitivity for 
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diagnosing fluoroquinolone, amikacin, capreomycin, and ethambutol resistance was 90%, 83%, 
87% and 59%, respectively. Specificity was 100% for diagnosing fluoroquinolone, amikacin and 
ethambutol resistance and 99% for diagnosing capreomycin resistance. 
Though the LPAs have significantly reduced the time to detection of MDR-TB, it is the recent 
development of Xpert MTB/RIF test that has been an immense leap forward in the rapid diagnosis 
of MDR M. tuberculosis.51 The Xpert MTB/RIF test utilizes a hemi-nested real-time PCR assay to 
amplify a MTB-specific sequence in the rpoB gene after which the wild type or mutated sequences 
are detected by molecular beacons.52 The assay is fully automated; the only manual step is the 
addition of a bactericidal and liquefying buffer to the sputum before transferring it to a disposable 
plastic cartridge. A major advantage of this approach is that the whole procedure is performed in 
closed cartridges, thereby avoiding cross-contamination of amplicons. 
The value of the Xpert MTB/RIF has been shown in two recent studies. The first study was a 
prospective, multi-country study of 1,730 patients suspected of having TB.52 Sensitivity of case 
detection for smear-positive patients was excellent (98.2%), but somewhat lower for smear-
negative patients (72.5%). This increased to 90% when Xpert MTB/RIF was performed on 
three sputum samples. The Xpert MTB/RIF correctly detected rifampin resistance in 209 of 
211 patients (99.1% sensitivity) and in all 506 patients with rifampin-susceptibible TB (100% 
specificity).(18) A second, very recent study assessed the operational feasibility of the Xpert 
MTB/RIF assays in routine primary health-care centres in tuberculosis-endemic settings.53 
In this second study, 6,648 participants with suspected (MDR) tuberculosis were enrolled. 
The Xpert MTB/RIF assay had a better sensitivity for detecting TB cases compared to direct 
microscopy (90.3% vs. 67.1%). Moreover sensitivity was not lower in HIV co-infected cases. 
Implementing the Xpert MTB/RIF assay reduced time to detection of rifampicin resistance to 
1 day compared to line-probe assays (20 days) and phenotypic drug-susceptibility testing (106 
days). This led to a reduced time-to-treatment of rifampicin resistant cases. This reduction 
was most clear in smear-negative, culture-positive cases, where time-to-treatment dropped 
from 56 to 5 day. 
In summary, drug resistance in M. tuberculosis emerges through the selection of mutant 
subpopulations. These mutant subpopulations can be detected via drug susceptibility testing. 
Phenotypic testing using solid medium methods have currently been replaced by the more 
rapid liquid culture systems. It has been the introduction of molecular methods that has been 
a game changer though, reducing time-to-detection of drug-resistant TB to a single day. This 
has made point-of-care testing for drug-resistant tuberculosis well within our reach. Indeed, 
we are yet again on the verge of a new era of diagnosing and treating TB. 
ChapTer TWo | Methods for drug susceptibility testing in tuberculosis Methods for drug susceptibility testing in tuberculosis | ChapTer TWo
28 29
referenCes
1. Lawn S D, Zumla A I. Tuberculosis. Lancet 2011;378(9785):57-72
2.  Tiemersma E W, van der Werf M J, Borgdorff M W, Williams B G, Nagelkerke N J. Natural history of 
tuberculosis: duration and fatality of untreated pulmonary tuberculosis in HIV negative patients: a 
systematic review. PLoS One 2011;6(4):e17601
3.  Raviglione M, Marais B, Floyd K, et al. Scaling up interventions to achieve global tuberculosis control: 
progress and new developments. Lancet 2012;379(9829):1902-1913
4.  Waksman S A, Reilly H C, Schatz A. Strain Specificity and Production of Antibiotic Substances: V. 
Strain Resistance of Bacteria to Antibiotic Substances, Especially to Streptomycin. Proc Natl Acad Sci 
U S A 1945;31(6):157-164
5.  Nobel Media AB. Tuberculosis [cited 2015, Jan 28]; Available from: http://www.nobelprize.org/
educational/medicine/tuberculosis/readmore.html
6. Streptomycin treatment of pulmonary tuberculosis. Br Med J 1948;2(4582):769-782
7.  Pyle M M. Relative numbers of resistant tubercle bacilli in sputa of patients before and during 
treatment with streptomycin. Proc Staff Meet Mayo Clin 1947;22(21):465-473
8.  Crofton J, Mitchison D A. Streptomycin resistance in pulmonary tuberculosis. Br Med J 
1948;2(4588):1009-1015
9.  Canetti G, Fox W, Khomenko A, et al. Advances in techniques of testing mycobacterial drug 
sensitivity, and the use of sensitivity tests in tuberculosis control programmes. Bull World Health 
Organ 1969;41(1):21-43
10.  Bottger E C. The ins and outs of Mycobacterium tuberculosis drug susceptibility testing. Clin 
Microbiol Infect 2011;17(8):1128-1134
11.  Mathema B, Kurepina N E, Bifani P J, Kreiswirth B N. Molecular epidemiology of tuberculosis: 
current insights. Clin Microbiol Rev 2006;19(4):658-685
12.  Gandhi N R, Nunn P, Dheda K, et al. Multidrug-resistant and extensively drug-resistant tuberculosis: 
a threat to global control of tuberculosis. Lancet 2010;375(9728):1830-1843
13.  Gillespie S H. Evolution of drug resistance in Mycobacterium tuberculosis: clinical and molecular 
perspective. Antimicrob Agents Chemother 2002;46(2):267-274
14.  Inderlied C, Pfyffer G E. Susceptibility test methods: Mycobacteria. In: Murray P, Baron J, Jorgensen J 
eds, Manual of Clinical Microbiology. 8 ed. Washingtion, DC: ASM Press; 2003:1149-1177
15.  Werngren J, Sturegard E, Jureen P, et al. Reevaluation of the critical concentration for drug 
susceptibility testing of Mycobacterium tuberculosis against pyrazinamide using wild-type MIC 
distributions and pncA gene sequencing. Antimicrob Agents Chemother 2012;56(3):1253-1257
16.  Canetti G, Froman S, Grosset J, et al. Mycobacteria: Laboratory methods for testing drug sensitivity 
and resistance Bull World Health Organ 1963;29:565-578
17.  van Ingen J, Boeree M J, van Soolingen D, Mouton J W. Resistance mechanisms and drug 
susceptibility testing of nontuberculous mycobacteria. Drug Resist Updat 2012;15(3):149-161
18.  World Health Organization. Policy guidance on drug-susceptibility testing (DST) of second-line 
antituberculosis drugs. Geneva: World Health Organization; 2008
19.  Heifets L B, Cangelosi G A. Drug susceptibility testing of Mycobacterium tuberculosis: a neglected 
problem at the turn of the century. Int J Tuberc Lung Dis 1999;3(7):564-581
20.  Coates A R, Mitchison D A. [The role of sensitivity tests in short-term chemotherapy]. Bull Int Union 
Tuberc 1983;58(2):111-114
21.  Roberts G D, Goodman N L, Heifets L, et al. Evaluation of the BACTEC radiometric method for 
recovery of mycobacteria and drug susceptibility testing of Mycobacterium tuberculosis from acid-
fast smear-positive specimens. J Clin Microbiol 1983;18(3):689-696
22.  Pfyffer G E, Bonato D A, Ebrahimzadeh A, et al. Multicenter laboratory validation of susceptibility 
testing of Mycobacterium tuberculosis against classical second-line and newer antimicrobial drugs by 
using the radiometric BACTEC 460 technique and the proportion method with solid media. J Clin 
Microbiol 1999;37(10):3179-3186
23.  Drobniewski F, Rusch-Gerdes S, Hoffner S, Subcommittee on Antimicrobial Susceptibility Testing 
of Mycobacterium tuberculosis of the European Committee for Antimicrobial Susceptibility 
Testing of the European Society of Clinical M, Infectious D. Antimicrobial susceptibility testing 
of Mycobacterium tuberculosis (EUCAST document E.DEF 8.1)--report of the Subcommittee on 
Antimicrobial Susceptibility Testing of Mycobacterium tuberculosis of the European Committee for 
Antimicrobial Susceptibility Testing (EUCAST) of the European Society of Clinical Microbiology and 
Infectious Diseases (ESCMID). Clin Microbiol Infect 2007;13(12):1144-1156
24.  Reisner B S, Gatson A M, Woods G L. Evaluation of mycobacteria growth indicator tubes for 
susceptibility testing of Mycobacterium tuberculosis to isoniazid and rifampin. Diagn Microbiol 
Infect Dis 1995;22(4):325-329
25.  Hanna B A, Ebrahimzadeh A, Elliott L B, et al. Multicenter evaluation of the BACTEC MGIT 960 
system for recovery of mycobacteria. J Clin Microbiol 1999;37(3):748-752
26.  Ardito F, Posteraro B, Sanguinetti M, Zanetti S, Fadda G. Evaluation of BACTEC Mycobacteria 
Growth Indicator Tube (MGIT 960) automated system for drug susceptibility testing of 
Mycobacterium tuberculosis. J Clin Microbiol 2001;39(12):4440-4444
27.  Rusch-Gerdes S, Domehl C, Nardi G, et al. Multicenter evaluation of the mycobacteria growth 
indicator tube for testing susceptibility of Mycobacterium tuberculosis to first-line drugs. J Clin 
Microbiol 1999;37(1):45-48
28.  Piersimoni C, Olivieri A, Benacchio L, Scarparo C. Current perspectives on drug susceptibility 
testing of Mycobacterium tuberculosis complex: the automated nonradiometric systems. J Clin 
Microbiol. 2006;44(1):20-28
29.  Horne D J, Pinto L M, Arentz M, et al. Diagnostic accuracy and reproducibility of WHO-endorsed 
phenotypic drug susceptibility testing methods for first-line and second-line antituberculosis drugs. 
J Clin Microbiol 2013;51(2):393-401
30.  Pfyffer G E, Palicova F, Rusch-Gerdes S. Testing of susceptibility of Mycobacterium tuberculosis 
to pyrazinamide with the nonradiometric BACTEC MGIT 960 system. J Clin Microbiol 
2002;40(5):1670-1674
31.  Chedore P, Bertucci L, Wolfe J, Sharma M, Jamieson F. Potential for erroneous results indicating 
resistance when using the Bactec MGIT 960 system for testing susceptibility of Mycobacterium 
tuberculosis to pyrazinamide. J Clin Microbiol 2010;48(1):300-301
32.  Rusch-Gerdes S, Pfyffer G E, Casal M, Chadwick M, Siddiqi S. Multicenter laboratory validation 
of the BACTEC MGIT 960 technique for testing susceptibilities of Mycobacterium tuberculosis to 
classical second-line drugs and newer antimicrobials. J Clin Microbiol 2006;44(3):688-692
33.  Kim S J, Espinal M A, Abe C, et al. Is second-line anti-tuberculosis drug susceptibility testing 
reliable? Int J Tuberc Lung Dis 2004;8(9):1157-1158
34.  Kim S J. Drug-susceptibility testing in tuberculosis: methods and reliability of results. Eur Respir J 
2005;25(3):564-569
35.  Ramaswamy S, Musser J M. Molecular genetic basis of antimicrobial agent resistance in 
Mycobacterium tuberculosis: 1998 update. Tuber Lung Dis 1998;79(1):3-29
36.  Zhang Y, Yew W W. Mechanisms of drug resistance in Mycobacterium tuberculosis. Int J Tuberc Lung 
Dis 2009;13(11):1320-1330
Methods for drug susceptibility testing in tuberculosis | ChapTer TWoChapTer TWo | Methods for drug susceptibility testing in tuberculosis
30 31
37.  World Health Organization. Molecular Line Probe Assays for rapid screening of patients at risk of 
MDR-TB. In. Geneva: World Health Organization; 2008 
38.  Palomino J C. Molecular detection, identification and drug resistance detection in Mycobacterium 
tuberculosis. FEMS Immunol Med Microbiol 2009;56(2):103-111
39.  Hillemann D, Rusch-Gerdes S, Richter E. Evaluation of the GenoType MTBDRplus assay for 
rifampin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and clinical 
specimens. J Clin Microbiol 2007;45(8):2635-2640
40.  Barnard M, Albert H, Coetzee G, O’Brien R, Bosman M E. Rapid molecular screening for multidrug-
resistant tuberculosis in a high-volume public health laboratory in South Africa. Am J Respir Crit 
Care Med 2008;177(7):787-792
41.  Bwanga F, Hoffner S, Haile M, Joloba M L. Direct susceptibility testing for multidrug-resistant 
tuberculosis: a meta-analysis. BMC Infect Dis 2009;9:67
42.  Global Laboratory Initiative. A roadmap for ensuring quality tuberculosis diagnostic services within 
national laboratory strategic plans. Geneva: World Health Organization; 2010
43.  Tortoli E, Marcelli F. Use of the INNO LiPA Rif.TB for detection of Mycobacterium tuberculosis DNA 
directly in clinical specimens and for simultaneous determination of rifampin susceptibility. Eur J 
Clin Microbiol Infect Dis 2007;26(1):51-55
44.  Ogwang S, Asiimwe B B, Traore H, et al. Comparison of rapid tests for detection of rifampicin-
resistant Mycobacterium tuberculosis in Kampala, Uganda. BMC Infect Dis 2009;9:139
45.  Acuna-Villaorduna C, Vassall A, Henostroza G, et al. Cost-effectiveness analysis of introduction of 
rapid, alternative methods to identify multidrug-resistant tuberculosis in middle-income countries. 
Clin Infect Dis 2008;47(4):487-495
46.  Quezada C M, Kamanzi E, Mukamutara J, et al. Implementation validation performed in Rwanda to 
determine whether the INNO-LiPA Rif.TB line probe assay can be used for detection of multidrug-
resistant Mycobacterium tuberculosis in low-resource countries. J Clin Microbiol 2007;45(9):3111-
3114
47.  O’Riordan P, Schwab U, Logan S, et al. Rapid molecular detection of rifampicin resistance facilitates 
early diagnosis and treatment of multi-drug resistant tuberculosis: case control study. PLoS One 
2008;3(9):e3173
48.  Hillemann D, Rusch-Gerdes S, Richter E. Feasibility of the GenoType MTBDRsl assay for 
fluoroquinolone, amikacin-capreomycin, and ethambutol resistance testing of Mycobacterium 
tuberculosis strains and clinical specimens. J Clin Microbiol 2009;47(6):1767-1772
49.  Antonova O V, Gryadunov D A, Lapa S A, et al. Detection of mutations in Mycobacterium 
tuberculosis genome determining resistance to fluoroquinolones by hybridization on biological 
microchips. Bull Exp Biol Med 2008;145(1):108-113
50.  Feuerriegel S, Cox H S, Zarkua N, et al. Sequence analyses of just four genes to detect extensively 
drug-resistant Mycobacterium tuberculosis strains in multidrug-resistant tuberculosis patients 
undergoing treatment. Antimicrob Agents Chemother 2009;53(8):3353-3356
51.  Helb D, Jones M, Story E, et al. Rapid detection of Mycobacterium tuberculosis and rifampin 
resistance by use of on-demand, near-patient technology. J Clin Microbiol 2010;48(1):229-237
52.  Boehme C C, Nabeta P, Hillemann D, et al. Rapid molecular detection of tuberculosis and rifampin 
resistance. N Engl J Med 2010;363(11):1005-1015
53.  Boehme C C, Nicol M P, Nabeta P, et al. Feasibility, diagnostic accuracy, and effectiveness of 
decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a 
multicentre implementation study. Lancet 2011;377(9776):1495-1505
Methods for drug susceptibility testing in tuberculosis | ChapTer TWoChapTer TWo | Methods for drug susceptibility testing in tuberculosis
32 33
ChapTer Three
Diagnosing pyrazinamide resistance in the 
Netherlands
adapted from: 
Simons S. O., van Ingen J., van der Laan T., Mulder A., Dekhuijzen P. N. R., Boeree M.B., van 
Soolingen D. Validation of pncA sequencing in combination with the Mycobacterial Growth 
Indicator Tube method to test susceptibility of Mycobacterium tuberculosis to pyrazinamide. 
Journal of Clinical Microbiology 2012; 50: 428-434
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absTraCT
Background: Pyrazinamide is important in the treatment of tuberculosis. Unfortunately, the 
diagnosis of pyrazinamide resistance is hampered by technical difficulties. We hypothesized 
that mutation analysis combined with the Mycobacteria Growth Indicator Tube (MGIT) 
phenotypic method would be a good predictor for pyrazinamide resistance. 
Design: We prospectively analyzed 1,650 M. tuberculosis isolates referred to our tuberculosis 
reference laboratory in 2008 and 2009. In our laboratory the MGIT 960 was used for 
pyrazinamide resistance screening. If a pyrazinamide resistant strain was detected, we 
performed a pncA gene mutation analysis. A second MGIT 960 susceptibility assay was 
performed afterwards to evaluate the accuracy of the pncA mutation analysis to detect true or 
false positive MGIT results. 
Results: We observed pyrazinamide resistance in 69 samples using a first MGIT 960 analysis. 
In a second MGIT 960 analysis, 47 of the 69 samples proved susceptible (68% false positivity). 
Sensitivity of nonsynonymous pncA mutations in detecting resistant isolates was 73% (95% 
CI, 61%-73%) and specificity 100% (95% CI, 95%-100%). 
Conclusions: A diagnostic algorithm combining phenotypic and molecular methods would 
have a 100% positive predictive value for detecting pyrazinamide-resistant isolates, indicating 
that such an algorithm, based on both methods, is a good predictor for pyrazinamide 
resistance in routine diagnostics. 
 
InTroDuCTIon
Pyrazinamide is one of the key components of primary drug therapy against tuberculosis, 
especially when multidrug-resistance has been diagnosed.1 The first clinical report of 
its antituberculosis activity dates to 1952.2 The addition of pyrazinamide and rifampicin 
to existing antituberculosis drug regimens has shortened therapy duration from 9 to 6 
months3 and not using pyrazinamide is correlated with treatment relapse.4 It is a unique 
antituberculosis drug because of its activity against the slowly growing, semidormant bacilli in 
acidic environments.3
The enzyme pyrazinamidase plays a crucial role in the mycobactericidal effect of 
pyrazinamide. This enzyme is expressed constitutively in the cytoplasm of M. tuberculosis.3 
Only after conversion of pyrazinamide into pyrazinoic acid by this enzyme is its deleterious 
effect expressed on the tubercle bacilli by destabilizing the membrane potential and affecting 
membrane transport function.5 Consequently, loss of pyrazinamidase activity leads to 
pyrazinamide-resistant tuberculosis bacilli.6
Nonsynonymous mutations in the gene encoding for pyrazinamidase, the pncA gene, lead 
to the loss of pyrazinamidase activity and are the major mechanism in the development 
of pyrazinamide resistance.7 Mutation analysis could thus be used to indirectly assess 
susceptibility to pyrazinamide.8 However, assessment of susceptibility based on pncA gene 
sequence analysis has its shortcomings. Mutations are highly diverse and widely dispersed 
throughout the pncA gene, limiting the chances of successful development of simple 
screening methods such as line probe assays. Furthermore, not all pyrazinamide-resistant M. 
tuberculosis isolates have mutations in this gene.9 For instance, mutations in the rpsA gene, 
encoding for ribosomal protein S1, have been described recently as a novel mechanism for 
pyrazinamide resistance.10 Phenotypic methods for testing susceptibility of M. tuberculosis to 
pyrazinamide remain the gold standard but also have their shortcomings. Both false-negative 
and false-positive resistant results are seen.11 In our experience false-positive resistant results 
(major errors) are seen most commonly. This observation has been noted by others also.12,13 In a 
study on susceptibility of 743 isolates tested in the Bactec Mycobacteria Growth Indicator Tube 
960 (MGIT 960) method, Chedore et al. found that 42% of strains that tested pyrazinamide 
resistant at first appeared to be in fact susceptible when the test was repeated.12 It is assumed 
that a large inoculum size impairs pyrazinamidase activity and leads to false-positive cases of 
pyrazinamide resistance.14 
Diagnosing pyrazinamide resistance in the Netherlands | ChapTer ThreeChapTer Three | Diagnosing pyrazinamide resistance in the Netherlands
36 37
Because the gold standard- phenotypic pyrazinamide susceptibility testing- can be 
hampered by false-positive results and mutation analysis is not a validated alternative yet, 
diagnosis of pyrazinamide resistance remains difficult. We hypothesized that in routine 
diagnostics, mutation analysis added to culture-based methods might be a good predictor 
for pyrazinamide resistance. More specifically, based on the observation that susceptibility 
testing by the MGIT 960 method is mainly hampered by major errors, we hypothesized that 
nonsynonymous pncA mutations would be able to differentiate between true-resistant and 
false-resistant results. 
MeThoDs
setting 
The National Institute for Public Health and the Environment (RIVM) is the national 
mycobacterial reference centre in the Netherlands. It receives all primary Mycobacterium 
tuberculosis complex isolates from the Netherlands. Annually, around 700 TB cases are culture 
positive which is around 70% of all TB notifications.15 Both multidrug resistance (MDR) and 
pyrazinamide resistance are estimated to be present in around 1% of these culture-positive 
cases.15,16  
Drug susceptibility to pyrazinamide 
Susceptibility to pyrazinamide was tested in the MGIT 960 method, according to the 
manufacturer’s instruction (Becton Dickinson, NJ, USA).17 Briefly, a pyrazinamide 
susceptibility test was prepared from a positive 7-ml MGIT tube using a direct inoculum 
obtained 1 to 2 days after a positivity signal. Two 7-mL Bactec MGIT 960 PZA medium tubes 
were used. One hundred µL of 8,000-mg/l pyrazinamide solution was added to one tube 
to achieve the recommended critical concentration of 100 mg/l (BD diagnostics). A 0.5-
mL volume of the seed inoculum was aseptically pipetted in this drug-containing tube. A 
drug-free control tube was inoculated with 0.5-mL of a 1:10 dilution of the seed inoculum. 
Tubes were placed in the MGIT 960 and automatically read. Read-outs were analyzed 
using EpiCenter software package.18 Mycobacterium tuberculosis isolates were considered 
pyrazinamide resistant if the MGIT 960 system gave concordant resistant results on two 
separate occasions. 
figure 1 
The PCR reading frame for the amplification of the pncA gene
Amplification and sequencing of the pncA gene 
The entire pncA open reading frame, as well as 133 bp upstream and 79 bp downstream, were 
amplified by PCR. Two overlapping amplicons, covering a 773 bp contiguous sequence (Figure 
1), were generated using the primers described in Table 1. PCR amplifications were carried out 
in a MBS 0.5S thermal cycler (Thermo Fisher Scientific, Waltham, MA, USA). Each reaction 
mixture (50 µL) contained 5 µl of 10-ng/µl template DNA, 25µl of HotStarTaq mastermix 
(Qiagen, Hilden, Germany), 10µl milliQ (Sigma-Aldrich, Irvine, Ayrshire, UK), 5µl of each 
primer (5 mM). The reaction mixtures were subjected to 15 min at 95°C, followed by 35 cycles 
of 60 s at 95°C for melting, 120 s at 60°C for annealing, 60 s at 72°C, and an elongation step 
at 72°C for 10 min. Unincorporated primers and dNTPs were removed from the reaction 
mixtures using EXOSAP_IT (USB Corporation, Cleveland, OH, USA) according to the 
manufacturer’s instructions. Automated DNA sequencing was performed using BigDye 
Terminator chemistry according to the protocol supplied by the manufacturer (Applied 
Biosystems, Foster City, CA, USA). All post-run analyses were performed using Bionumerics 
software version 6.5 (Applied Maths, Sint-Martens-Latem, Belgium). 
 561 pb pncA
773 pb contiguous sequence
pncA_2F
pncA_1F pncA_1R
pncA_2R
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Table 1  
PncA primer sequences
primer name sequence 5’ to 3’ position(a)
pncA_1F GGC CGC GAT GAC ACC TCT -133
pncA_1R GCC GCA GCC AAT TCA GCA GT 305
pncA_2F CGA AGC GGC GGA CTA CCA TCA CG 180
pncA_2R CCC CAC CTG CGG CTG CGA ACC 639
(a) Numerical position on the primers as determined from the start codon of the pncA gene.
Genotyping 
To assess potential associations between M. tuberculosis genotypes and pyrazinamide 
resistance, we performed IS6110 restriction fragment length polymorphism (RFLP) typing, 
spoligotyping and Mycobacterial Interspersed Repetitive Units-Variable Number of Tandem 
Repeats (MIRU-VNTR) typing of all isolates using previously published methods.19-21
analysis 
To answer our research question, we prospectively analyzed all M. tuberculosis isolates sent 
to our laboratory for resistance testing in 2008 and 2009. Mycobacterium bovis isolates 
were excluded since they are exclusively pyrazinamide resistant and carry only one specific 
pncA gene mutation. This study was set up as a pragmatic laboratory-based study using a 
diagnostic algorithm close to routine clinical practice. In our laboratory the MGIT 960 was 
used for pyrazinamide resistance screening. If a pyrazinamide-resistant strain was detected, 
we performed a pncA gene mutation analysis. A second MGIT 960 susceptibility assay was 
performed afterwards to evaluate the accuracy of the mutation analysis to detect true or false 
positive MGIT results.
The primary outcome was the diagnostic accuracy of pncA mutation analysis to detect true 
pyrazinamide resistance among M. tuberculosis isolates with a first resistant results from 
a MGIT 960 pyrazinamide susceptibility analysis. Diagnostic accuracy was expressed as 
sensitivity, specificity, positive and negative predictive value using 2 x 2 contingency tables. 
Estimates are given in percentages with a 95% confidence interval (95% CI).
resulTs
predicting pyrazinamide resistance 
During 2008 and 2009, 1,650 M. tuberculosis isolates were sent for resistance testing to our 
laboratory (Figure 2). We observed pyrazinamide resistance in 69 out of 1,650 samples after 
the first MGIT 960 analysis. However, in the second MGIT 960 test, 47 of the 69 samples 
proved susceptible and 22 were confirmed to be resistant, indicating a false-positive rate of 
68% in the first MGIT 960 test. Sensitivity of the nonsynonymous pncA mutation in detecting 
pyrazinamide true resistant isolates was 73% (95% CI, 61%-73%) and specificity was 100% 
(95% CI, 95%-100%). The positive predictive value of the nonsynonymous pncA mutation in 
detecting pyrazinamide resistance was 100% (95% CI, 85%-100%) and the negative predictive 
value was 89% (95% CI,84%-89%). The overall accuracy of nonsynonymous pncA mutations 
for detecting pyrazinamide-resistant isolates was 91% (95% CI, 84%-92%). 
figure 2  
Diagnostic accuracy of pncA mutation analysis added to bacteriological susceptibility testing in 
detecting false and true positive pyrazinamide-resistant M. tuberculosis isolates
1,650 isolates
69 pyrazinamide resistant in first  
MGIT analysis
47 susceptible after  
second MGIT analysis  
(= true negative)
6 resistant after second  
MGIT analysis  
(= false negative)
53 no pncA mutation or  
synonymous mutation
16 resistant after  
second MGIT analysis  
(= true positive)
16 nonsynonymous pncA  
mutation
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pyrazinamide-resistant cases in the netherlands
Twenty-two isolates from 15 patients in 2008 and 2009 were pyrazinamide resistant; their 
baseline characteristics, MIRU-VNTR typing results, drug susceptibility profiles and pncA 
sequence analysis are described in Table 2. A wide variety of mutations was seen and one 
mutation was observed in the putative promoter region (NLA000801739). Some of the strains 
had the same type of mutations but different MIRU-VNTR patterns, indicating that they were 
truly different strains that had coincidently acquired the same type of mutation. For example, 
patients NLA000800922 and NLA000800620 had the same mutation of his71 →Gln, yet 
MIRU-VNTR analysis indicated that they were different M. tuberculosis strains. 
Interestingly, 5 patients had pyrazinamide resistant isolates that did not carry any pncA 
mutation, neither in the gene itself, nor in the putative pncA promoter region. Three of 
these patients were in fact pyrazinamide monoresistant (NLA000800519, NLA000901231, 
NLA000801755). We performed both the MGIT 960 analysis as the pncA mutation three 
times to confirm these results. MIRU-VNTR analysis indicated that these were all different 
strains (Table 2). 
Table 2
Characteristics of pyrazinamide-resistant tuberculosis cases in the Netherlands, 2008-2009
age 
(years)
sex
(M/V)
strain VnTr resistance 
to other 
drugsa
pncA mutation
nucleotide 
changes
amino acid 
changes
29 M NLA000800326 9002568 
9002582
H, RIF, E, 
CLR
 A to C at 502  Thr168Pro
84 M NLA000800465 9002610 - G deletion at 60 Frame shift
24 M NLA000800620 9002653 - T to A at 213 His71Gln
43 M NLA000800922 9003512
9003513
- T to A at 213 His71Gln
26 V NLA000801739 9002811 H -12 promoter 
mutation T -> C
Frame shift
41 M NLA000801926 9002939 H GAG deletion at 
430 
Glu144  
deletion
44 M NLA000800594 9003531 H, RIF, E, 
AMK, CIP
G insertion at 218 Frame shift
29 V NLA000900573 9003015 H, RIF, E, 
AMK, CIP, 
KAN, MOX 
G insertion at 516 Frame shift
17 V NLA000901644 9000061 H, RIF G to A at 3  Met1Ile
25 M NLA000902122 9000408 H, RIF, E, 
RFB
G to C at 289 Gly97Arg
16 M NLA000800519 9003284 - - -
26 M NLA000901231 9002622 - - -
24 V NLA000801502 9002838 H - -
47 M NLA000801595 9000055 H - -
31 M NLA000801755 9002965 - - -
a  Drug names: H, isoniazid; RIF, rifampicin; RFB, rifabutin; E, ethambutol; CLR, clarithromycin; AMK, amikacin;  
CIP, ciprofloxacin; KAN, kanamycin; MOX, moxifloxacin
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Genotype family of pyrazinamide-resistant cases 
Since we found some unusual pyrazinamide monoresistant cases, we wondered whether the 
respective M. tuberculosis isolates were clustered in certain genotype families. We therefore 
determined the genotype family of all resistant isolates (Figure 3). One spoligotype was not 
available (NLA000801926). Although a relatively high percentage of the Beijing genotype 
(5 out of 15, 33%) was noted in this sample, no specific genotype family clustering was seen 
among the pyrazinamide (mono)resistant cases.
DIsCussIon
This study shows that mutation analysis added to culture-based methods is a good predictor 
for pyrazinamide resistance in routine diagnostics. In our experiments, we have shown that 
in a series of 69 isolates found resistant at first instance by the MGIT 960, 68% were false-
resistant and that nonsynonymous pncA mutations could identify accurately these false-
positive results. Moreover, a diagnostic algorithm combining the MGIT 960 and mutation 
analysis could correctly identify pyrazinamide-resistant cases.  
Our results are in concordance with a recent meta-analysis by Chang and co-workers, who also 
showed that nonsynonymous pncA mutations can detect pyrazinamide resistance accurately.8 
The present study has some important strengths. First, we validated our results by retesting 
discordant pyrazinamide results, thereby minimizing major errors. Second, it was set up as 
a pragmatic trial enabling direct applicability of our diagnostic algorithm in everyday clinical 
diagnostics in a variety of settings. 
Our results extend our knowledge on the role of molecular methods in the diagnosis 
of pyrazinamide resistance. The first studies on the association of pncA mutations and 
pyrazinamide resistance found mutations in up to 97% of pyrazinamide-resistant cases.22-24 
However, these were mainly selected pyrazinamide-resistant cases with a high MIC.  
Subsequent studies have shown lower prevalence of pncA mutations in pyrazinamide-
resistant cases.9,25 We also found a lower prevalence of nonsynonymous pncA mutations 
(67% of isolates). Given our experimental setup, our results may better reflect pyrazinamide 
resistance found in daily routine in a country with a low prevalence of pyrazinamide 
resistance. Zhang et al. have argued that such a finding may in part reflect incorrect 
pyrazinamide susceptibility testing.3 In our experiments both the MGIT 960 analysis as well 
as the mutation analysis yielded identical results three times at separate occasions. Hence, 
measurement errors cannot explain these findings. Pyrazinamide resistance in strains with 
wild type pncA sequences can alternatively be explained by the presence of a pncA regulatory 
gene outside our reading frame, or by pyrazinamide resistance mechanisms other than the 
effect on pyrazinamidase,3 such as the recent finding of mutations in the rpsA gene.10 
Based on our results, we propose an algorithm, depicted in Figure 4, to assess pyrazinamide 
resistance in routine clinical diagnostics. After a first round of MGIT 960 testing, all 
isolates labeled resistant should undergo pncA gene sequence analysis. A nonsynonymous 
mutation has a positive predictive value of 100% for a true pyrazinamide resistant isolate. If a 
synonymous mutations or a wild type pncA gene is found, the MGIT 960 analysis should be f
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repeated. Given the shorter turnaround time of mutation analysis, incorporating molecular 
methods has the potential of shortening the diagnosis of pyrazinamide resistance. It is to 
be seen if such shortening will optimize treatment of tuberculosis patients, especially for 
multidrug-resistant TB patients in which pyrazinamide susceptibility testing is essential.1
figure 4 
Flow diagram to assess pyrazinamide resistance in a M. tuberculosis isolates in routine diagnostics, 
combining phenotypic and molecular methods
Using the diagnostic algorithm proposed in this study (Figure 4), we found 15 cases of 
pyrazinamide resistance in the Netherlands in a two-year period (Table 4). The total number of 
cases diagnosed with culture-confirmed tuberculosis these 2 years was 1,504.15 The prevalence 
of pyrazinamide resistance among culture-positive M. tuberculosis cases in the Netherlands 
was therefore 1.0%. Five out of 15 (33%) cases had multidrug-resistant tuberculosis (MDR-TB) 
which is significantly higher than the general prevalence of MDR-TB in the Netherlands. Such 
higher prevalence of pyrazinamide resistance in multidrug-resistant tuberculosis is commonly 
seen.26 A relatively high number of Beijing genotype strains was seen because the Beijing 
genotype is associated with MDR-TB in Europe.27 Three out of 15 pyrazinamide-resistant 
cases found in this study were pyrazinamide monoresistant. Pyrazinamide monoresistance 
has been described previously but is rare.28,29 For instance, in a study from the United States, 
only 3 out of 1,916 isolates proved pyrazinamide monoresistant,29 which is a percentage similar 
to our findings (3 out of 1,650 isolates). However, though repeated analysis yielded the same 
result, we cannot rule out that we made a systematic measurement error giving repeated false-
resistant MGIT results. 
A limitation of this study is the use of the MGIT 960 as the gold standard. Though the proper 
gold standard for pyrazinamide resistance is not established yet, it is accepted that the Bactec 
radiometric method is probably most reliable.3 We choose the MGIT 960 as the gold standard 
since current meta-analyses suggest that the MGIT has comparable test performances and 
could therefore be used as reference DST assay.8,11 Moreover, there is a legitimate concern 
about the disposal of radioactive waste when the Bactec radiometric method is used. Third, 
Bactec 460 machinery is phased out, and supplies will no longer be available, limiting the 
applicability of a diagnostic algorithm incorporating this method. Last, other candidates for 
the gold standard are scarce. The 7H10 agar-based testing methods are considered less reliable.23 
Susceptibility testing on solid Löwenstein-Jensen media is acceptable according to some 
experts,3 but is not used for drug susceptibility testing in most laboratories in the Western 
world anymore. The Wayne method might be another alternative.8 However, the Wayne 
method requires a sufficient number of bacilli for detecting pyrazinamidase activity making 
this test prone to false resistance testing which was exactly what we tried to minimize in our 
diagnostic setup. Moreover, at the time we undertook our study this assay was considered less 
sensitive for diagnosing pyrazinamide resistance.30
Though the MGIT can be regarded as a surrogate gold standard, this study confirms earlier 
observation by others that the MGIT reports false resistant isolates.12,13 Comparable high 
numbers of false positive resistant culture results have been reported by other researchers 
using the MGIT 960 technique. False phenotypic resistance is mainly caused by a well-
known difficulty in pyrazinamide susceptibility testing: the use of large inoculums. A 
large inoculum size increases pH and thereby inactivates pyrazinamidase.14 An alternative 
explanation for the high false resistance rate could be the use a relatively low breakpoint in 
the MGIT (100 mg/l) thereby wrongly labelling susceptible or intermediately susceptible 
isolates as resistant.8 Others have suggested that 200 mg/l or 300 mg/l would be a more 
appropriate resistance breakpoint.3 Because we wanted to stay close to routine practice, we 
choose the 100 mg/l as prescribed by the manufacturer.17 Given the high rates of false positive 
results, a first notification of pyrazinamide resistance in liquid media, such as the MGIT 960, 
should be interpreted with caution. We would recommend to repeat the MGIT 960 giving 
Culture 1st MGIT pncA analysis 2nd MGIT
prevalence of PZA 
resistance =
1%
positive predictive 
value (PPV) of 
resistance in first 
MGIT 960 = 32%
PPV of resistance 
if nonsynomous 
mutation found = 
100%
PPV of resistant  
result in second  
MGIT 960 = 
100%
culture positive  
M. tuberculosis
first MGIT 960 
resistant 2nd MGIT 960 
resistant
nonsynonymous 
pncA mutation
first MGIT 960 
susceptible 2nd MGIT 960 
susceptible
wild type or 
synonymous  
pncA mutation
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special attention to the inoculum size and constitution. The present study highlights another 
possibility, namely, the use of a mutation analysis as an adjunct to the MGIT 960 as depicted 
in Figure 4. 
The issue underlying these difficulties in interpreting pyrazinamide resistance testing, is the 
paucity of adequate in vivo data. Although pyrazinamide has been a drug available for fifty 
years, there are currently no studies published that linked in vitro pyrazinamide resistance to 
important in vivo clinical outcomes. There is some evidence that treatment outcome is worse 
in the presence of initial resistance in general, but this is not specified for pyrazinamide.4 The 
most important obstacle for sound clinical data are the technical difficulties and the limited 
standardization in drug susceptibility testing as described earlier. Our proposed flow diagram 
may help in standardizing pyrazinamide resistance testing and may be used in future studies 
on clinical outcome.
In summary, we have shown that a combination of MGIT 960 phenotypic pyrazinamide 
susceptibility testing and pncA mutation analysis provides a good predictor of pyrazinamide 
resistance in routine diagnostics. Nonsynonymous pncA mutations are able to differentiate 
between true resistant and falsely resistant MGIT 960 results. Given the high number of false 
positive results from phenotypic methods, our findings suggest that using mutation analysis 
improves and fastens pyrazinamide susceptibility testing. Based hereupon, we propose a 
diagnostic algorithm combining both phenotypic and molecular tests for the assessment of 
pyrazinamide resistance.
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ChapTer four
The role of rpsA gene sequencing in the  
diagnosis of pyrazinamide resistance
adapted from: 
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Role of rpsA gene sequencing in the diagnosis of pyrazinamide resistance.  
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Dear sir,
We read with great interest the article by Alexander and colleagues on the frequency of rpsA 
mutations in pyrazinamide-susceptible and resistant isolates with a wild-type pncA gene.1 
In contrast to the report of Shi and colleagues,2 Alexander and colleagues could not find any 
rpsA mutations in pyrazinamide-resistant isolates and concluded that the analysis of the rpsA 
gene has no role in the diagnosis of pyrazinamide resistance.
Intrigued by their observations, we re-examined our sample of pyrazinamide-resistant isolates 
with wild-type pncA sequences, published previously in this journal (Table 1).3 This sample 
consisted of 5 isolates. rpsA gene sequencing was performed using the same methods as those 
of Alexander and colleagues.1 Sequencing the rpsA gene revealed an G-to-A nucleotide change 
at position 778 in one isolate, leading to an amino acid change from valine to isoleucine. No 
changes in the rpsA gene were seen in the other four isolates. So, in contrast to the findings 
of Alexander and colleagues, we were able to find a non-synonymous rpsA mutation in 
pyrazinamide-resistant isolates with a wild-type pncA gene, albeit in a minority of cases.
Table 1  
RpsA mutations in pyrazinamide resistant isolates with a wild type pncA gene
patient no. resistance  
profilea
pncA gene rpsA mutation
nucleotide change amino acid change
NLA000800519 Z wild type G to A at 778 Val260Ile
NLA000901231 Z wild type - -
NLA000801502 Z, H wild type - -
NLA000801595 Z, H wild type - -
NLA000801755 Z wild type - -
a Drug names: H = isoniazid, Z= Pyrazinamide
Does this mean that rpsA sequencing could have a role in pyrazinamide resistance testing? To answer 
this question, we also reanalyzed our data on the accuracy of pncA gene sequencing in the diagnosis 
of pyrazinamide resistance.3 Incorporating rpsA gene sequencing in our proposed diagnostic 
algorithm would increase sensitivity from 72% to 77%, indicating that rpsA gene sequencing has only 
a modest effect on sensitivity. The finding of additional mutations correlated with pyrazinamide 
resistance, such as in the rpsA gene, is fascinating and offers important insights into the intracellular 
targets and behaviours of pyrazinamide. With the increasing possibilities for efficient determination 
of mutations, this could upgrade the reliability of testing resistance to this increasingly important 
antituberculosis drug.4 However, we agree with Alexander and colleagues that the role of rpsA gene 
sequencing itself in the diagnosis of pyrazinamide resistance is modest at best.
reply by f. b. Jamieson 
Comment in: Alexander D. C., Ma J. H., Guthrie J. L., Blair J., Chedore P., Jamieson F. B.  
Reply to "role of rpsA gene sequencing in diagnosis of pyrazinamide resistance".  
Journal of Clinical Microbiology 2013; 51: 383 
We appreciate the comments made by Simons and colleagues regarding the value of rpsA gene 
sequencing in the diagnosis of pyrazinamide resistance. The diversity of mutations associated 
with drug resistance in Mycobacterium tuberculosis has been a challenge to the sensitivity 
and predictive value of molecular diagnostic tools. For most clinical laboratories, full-gene 
sequencing of all resistance-associated loci is not a feasible approach.5 Until rapid, cost-effective 
methods for identifying every mutation in every strain are developed, operational demands 
dictate that routine diagnostic algorithms focus on the most common and informative targets. 
For example, most molecular assays target only the short “rifampin resistance-determining 
region” of rpoB, even though mutations outside this region can confer resistance to rifampin.6,7 
Consistently, studies have identified pncA mutations in 80% of pyrazinamide-resistant 
Mycobacterium tuberculosis isolates.8 The paper by Shi and colleagues raised the possibility 
that rpsA mutations may explain resistance in wild-type pncA (pncAWT) strains.2 However, in 
our clinical collection of pyrazinamideresistant isolates, no non-synonymous mutations were 
observed.1 Although our colleagues report that 1 of the 5 pncAWT strains  
they examined contained a rpsA mutation, they do not indicate if they confirmed the phenotypic 
impact of the G778→ A/Val260→ Ile change (e.g., by cloning the mutant rpsA gene into a 
pyrazinamide-sensitive strain and measuring a decrease in susceptibility).
To be clear, we do not discount a role for rpsA, but the current data indicate that rpsA mutations 
account for resistance in only a small subset of strains. We also concede that a two-step 
approach, where only pncAWT isolates are subjected to rpsA sequencing, may be useful. However, 
our initial intent was routine analysis of both genes, just as common algorithms for investigating 
isoniazid resistance target both katG and inhA.
Irrespective of the possible value of rpsA sequencing, it is evident that additional determinants 
of pyrazinamide resistance remain to be characterized. Notably, two of the isolates described 
by Simons and colleagues exhibited resistance to both pyrazinamide and isoniazid. We 
also observed this resistance pattern among pncAWT and rpsAWT isolates. Considering that 
pyrazinamide and isoniazid have somewhat similar chemical structures and that both are 
administered as prodrugs, we have wondered if some shared mechanism may mediate resistance 
to both agents. Thorough analysis of such strains may uncover novel determinants of resistance 
to pyrazinamide and other antimycobacterial agents and provide useful information for the 
effective treatment of tuberculosis.
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ChapTer fIVe
Detecting pyrazinamide resistance in  
multidrug-resistant tuberculosis
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absTraCT
Background: There is an urgent need for rapid and accurate diagnosis of pyrazinamide-
resistant multidrug-resistant tuberculosis (MDR-TB). No diagnostic algorithm has been 
validated in this population. We hypothesized that pncA sequencing added to rpoB mutation 
analysis can accurately identify patients with pyrazinamide-resistant MDR-TB. 
Methods: We identified from the Dutch national database (2007-11) patients with a 
positive M. tuberculosis culture containing a mutation in the rpoB gene. In these cases, we 
prospectively sequenced the pncA gene. Results from the rpoB and pncA mutation analysis 
(pncA added to rpoB) were compared with phenotypic susceptibility testing results to 
rifampicin, isoniazid and pyrazinamide (reference standard) using the Mycobacteria Growth 
Indicator Tube (MGIT) 960 system. 
Results: We included 83 clinical M. tuberculosis isolates containing rpoB mutations in the 
primary analysis. Rifampicin resistance was seen in 72 isolates (87%), isoniazid resistance in 
73 isolates (88%) and MDR-TB in 65 isolates (78%). Phenotypic reference testing identified 
pyrazinamide-resistant MDR-TB in 31 isolates (48%). Sensitivity of pncA sequencing added 
to rpoB mutation analysis for detecting pyrazinamide-resistant MDR-TB was 96.8%, the 
specificity was 94.2%, the positive predictive value was 90.9%, the negative predictive value 
was 98.0%, the positive likelihood was 16.8 and the negative likelihood was 0.03.
Conclusion: Pyrazinamide-resistant MDR-TB can be accurately detected using pncA 
sequencing added to rpoB mutation analysis. We propose to include pncA sequencing in every 
isolate with a rpoB mutation, allowing for stratification of MDR-TB treatment according to 
pyrazinamide susceptibility.
InTroDuCTIon
Pyrazinamide-based treatment of multidrug-resistant tuberculosis (MDR-TB) has been the 
standard in the past decades and its importance has only become clearer in recent years.1 
Studies have suggested that pyrazinamide (PZA) might work synergistically with other 
anti-tuberculosis (anti-TB) drugs such as fluoroquinolones and bedaquiline.2,3 Moreover, 
combining pyrazinamide in new anti-TB treatment regimens might have the potential to 
shorten MDR-TB treatment duration.3
Despite this potential of PZA in MDR-TB treatment, the high prevalence of pyrazinamide 
resistance in MDR-TB4 and the troublesome drug susceptibility testing (DST) to PZA5 have 
dampened enthusiasm. Phenotypic DST using the MGIT 960 system is currently considered 
the gold standard, but it is prone to false-resistant errors.6 Screening for mutations in the 
pncA gene might be an alternative proxy for PZA resistance.5 Indeed, a recent meta-analysis 
has suggested that within an MDR-TB population, pncA sequencing has good diagnostic 
accuracy.4
Sequencing the pncA gene might therefore prove to be the DST assay to guide pyrazinamide-
based MDR-TB treatment. However, no formal study has been published evaluating the 
accuracy of such a molecular-based diagnosis of PZA resistance in MDR-TB. We hypothesized 
that pncA sequencing added to rpoB mutation analysis can accurately identify these PZA-
resistant MDR-TB patients. We chose rpoB mutation analysis because this may be a good 
indicator for MDR-TB in high-burden settings.7 To test our hypothesis, we prospectively 
sequenced the pncA gene in patient isolates with a known rpoB mutation and compared 
results with phenotypic drug susceptibility results to rifampicin, isoniazid and pyrazinamide. 
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MaTerIals anD MeThoDs
study setting 
This study was performed at the National Institute for Public Health and the Environment 
(RIVM), which receives all primary M. tuberculosis complex isolates from the Netherlands.8 
Yearly, around 1-2% of all TB notifications in the Netherlands are considered to be MDR-TB.8 
Pyrazinamide resistance in the Netherlands is detected in 1% of all TB cultures6 and in 23% of 
MDR-TB cases.9 
study population 
We retrospectively identified from our national database (2007-2011) all patients with a 
positive M. tuberculosis culture containing a rpoB mutation (rpoB+ patients). We used the 
Genotype MTBDRplus kit (Hain Lifesciences, Nehren, Germany) to screen for mutations in 
the rpoB gene. If an rpoB mutation was found by the line probe assay, the hotspot region of the 
rpoB gene was sequenced as previously described.10
phenotypic drug susceptibility testing 
We tested susceptibility to rifampicin, isoniazid and pyrazinamide in all rpoB+ patients 
using the Mycobacteria Growth Indicator Tube (MGIT) 960 system (Becton Dickinson, 
Erembodegem, Belgium). Breakpoint concentrations were set at 1.0 mg/l (rifampicin), 0.1 
mg/l (isoniazid) and 100 mg/l (pyrazinamide), according to the manufacturer’s instruction. 
The DST results for rifampicin and isoniazid resistance were extracted from our database for 
a first available isolate of an rpoB+ patient. DST to these anti-TB drugs had been tested before 
this study within the context of routine diagnostic service. Multidrug-resistant M. tuberculosis 
was defined as isolates being resistant at least to rifampicin and isoniazid.1
For susceptibility testing to PZA, cultures from rpoB+ patients were obtained from our -70 
°C freezer and sub-cultured in MGIT medium. Five experienced technicians prospectively 
tested for susceptibility to PZA using the MGIT PZA kit (pH 5.9) and an inoculum size of 0.5 
ml.6 Test results were then compared with previous MGIT 960 results for PZA susceptibility 
testing from our database, which had been performed within the context of routine diagnostic 
service. Isolates were considered pyrazinamide resistant if the MGIT 960 testing yielded 
concordant resistant results and susceptible if testing yielded concordant susceptible results. 
Thirteen isolates with discordant results were subjected to a third PZA susceptibility testing 
and were sent to an external laboratory for confirmation by MGIT testing (ITM, Antwerp, 
Belgium). After this second round of testing, concordant DST results were seen in all isolates 
(11 resistant, 2 susceptible). 
pncA mutation analysis 
The entire pncA open reading frame, as well as 133 bp upstream and 79 bp downstream, were 
amplified by PCR, as described previously.6 Three experienced technicians carried out all 
procedures and readings. Blinding to the phenotypic reference test could not be guaranteed 
for every reading. Nonsynonymous pncA mutations (pncA+) were considered an indicator for 
pyrazinamide resistance.
statistical analysis 
The primary analysis was the diagnostic accuracy of finding a nonsynonymous pncA mutation 
in rpoB+ isolate (pncA added to rpoB) to identify PZA-resistant MDR-TB isolates. The study 
population included all patients with an M. tuberculosis infection carrying an rpoB mutation. 
The index test consisted of pncA sequencing. The MGIT 960 test results for rifampicin, 
isoniazid and pyrazinamide were used as the phenotypic reference test. Only isolates with 
duplicate pyrazinamide test results were included in the analysis, limiting false-resistance 
results. Inconclusive test results from the pncA sequencing were grouped with negative 
results, because in practice these patients would not be treated on the basis of mutation 
analysis but on the basis of results of the final phenotypic susceptibility tests.11 
Diagnostic accuracy (pncA added to rpoB) was expressed as sensitivity, specificity, positive/
negative predictive value and positive/negative likelihood ratios using 2x2 contingency 
tables and OpenEpi software (version 2.3.1; Rollins School of Public Health, Emory 
University [http://www.OpenEpi.com]). The Wilson score method was used to calculate 
95% confidence intervals around the proportions. This report was written following STARD 
guidelines.12 
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resulTs
study population 
We identified 85 patients with a positive M. tuberculosis culture containing an rpoB mutation 
(rpoB+ patients), of whom 83 were enrolled (Figure 1). The median age of the included patients 
was 27 years and 43% were males (Table 1). The majority of patients were foreign-born and 
23 patients came from high-burden MDR-TB countries. One patient was excluded because 
no source material was available for pncA sequencing. This isolate was considered to be PZA 
and rifampicin susceptible, but isoniazid resistant during routine diagnostics. Another isolate 
was excluded because no source material was available anymore for duplicate pyrazinamide 
phenotypic susceptibility testing. This latter isolate had been designated as PZA-susceptible, 
MDR-TB during routine diagnostics. 
Table 1  
Demographic characteristic of the study patients
all patients (n=83)
Median age in years (IQR) 27 (23-33)
Sex (male) 36 (43%)
Nationality
     Foreign-born 78 (94%)
     Born in a high-burden MDR-TB countrya 23 (28%)
TB localization
     Pulmonary 56 (67%)
     Extrapulmonary 27 (33%)
MDR-TB 65 (78%)
Resistance to pyrazinamideb 32 (39%)
a  The following 27 countries are considered as high-burden MDR-TB countries by the WHO: Armenia, Azerbaijan, 
Bangladesh, Belarus, Bulgaria, China, Democratic Republic of Congo, Estonia, Ethiopia, Georgia, India, Indonesia, 
Kazakhstan, Kyrgizstan, Latvia, Lithuania, Myanmar, Nigeria, Pakistan, Phillipines, Republic of Moldova, Russian Fed-
eration, South Africa, Tajikistan, Ukraine, Uzbekistan, and Viet Nam.
b  thirty-one isolates were pyrazinamide-resistant MDR-TB. One isolate was pyrazinamide resistant, isoniazid resistant 
but rifampicin susceptible.
figure 1  
Study Algorithm
Abbreviations: FN, false-negative index test result: FP, false positive index test result: INH, isoniazid: MDR-TB, 
multidrug-resistant tuberculosis: MGIT, mycobacterial growth indicator tube; PZA, pyrazinamide: Rif, rifampicin: 
rpoB+ patient, patients with a positive M. tuberculosis culture carrying a mutation in the rpoB gene: -r, resistant:  
-s, susceptible: TN, true-negative index test result: TP, true-positive index test result.
85 eligible rpoB+ patients
83 rpoB+ patients
pncA mutation analysis
(index test)
excluded (N = 2):
1x no pncA mutation 
analysis 
1x no duplicate PZA  
MGIT result
33 Nonsynonymous  
mutations
MGIT 960 
(reference standard)
1 inconclusive result
MGIT 960 
(reference standard)
48 TN:
31 PZA-s, MDR-TB
7 PZA-s, Rif-r, INH-s
7 PZA-s, Rif-s, INH-r
3 PZA-s, Rif-s, INH-s
1x FN:
1 PZA-r, MDR-TB
1 TN:
1 PZA-s, MDR-TB
0 x FN:
-
30 x TP: 
30 PZA-r, MDR-TB 
3 x FP: 
2 PZA-s, MDR-TB
1 PZA-r, Rif-s, INH-r
49 wild type pncA 
or synonymous mutations
MGIT 960 (reference standard)
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phenotypic drug susceptibility testing (reference test) 
We detected rifampicin resistance in 72 rpoB+ patients (87%), isoniazid resistance in 73 
rpoB+ patients (88%) and pyrazinamide resistance in 32 (39%) rpoB+ patients. MDR-TB was 
identified in 65 rpoB+ patients (78%); isolates of eleven rpoB+ patients proved rifampicin 
susceptible in the MGIT system. Most of these isolates carried mutations at specific codon 
positions (Table 2). Phenotypic methods identified 31 (48%) PZA-resistant MDR-TB out of 65 
MDR-TB isolates (Phenotypic reference test result). 
Table 2  
Association of non-synonymous mutations in the rpoB or pncA gene with phenotypic drug suscepti-
bility (DST) to either rifampicin or pyrazinamide
Drug locus DsTa Mutationb
Pyrazinamide pncA Resistant Met1Ile, Met1Thr, Ala28Thr, Ala46Val, 
Thr47Ala, Asp49Glu, His51Arg, His57Tyr, 
Pro62Leu, Pro69Ser, Thr76Pro, Leu85Arg, 
Phe94Cys, Gly97Arg, Tyr103stop, 
Ser104Arg, Thr135Pro, Thr168Pro, 
Met175Ile, Val180Phe, Leu182Ser
Susceptible Asp129Asn, Val155Met
Rifampicin rpoB Resistant Leu449Arg,c Asp516Ala, Asp516Val,  
Asp516Tyr,d Pro520Ser,c Ser522Leu, 
His526Ala, His526Asp, His526Leu,d 
His526Tyr, Ser531Leu, Ser531Met,  
Ser531Phe, Leu533Proc
Susceptible Leu511Pro, Met515Leu,c Asp516Tyr,d 
His526Asn, His526Leu,d Ser531Cys,  
Leu533Pro
a Drug susceptibility was tested using the MGIT 960 system. Susceptibility to pyrazinamide was tested in duplicate. 
b The pncA mutations not found in the DreamDB database (http://www.tbdreamdb.com) are highlighted in bold.  
c  The following mutations were only seen in combination with other mutations: Leu449Arg with His526Leu, 
Met515Leu with Leu511Pro, Pro520Ser with Ser522Leu and Leu533Pro with Asp516Ala.
d  The following mutations were noted both in susceptible as well as in resistant cases: Asp516Tyr (1 susceptible, 1 
resistant) and His526Leu (3 susceptible, 1 resistant)
Diagnostic accuracy of mutation analysis 
We performed pncA mutation analysis in all isolates from the 83 rpoB+ patients (Figure 1). 
Forty-nine wild type pncA genes or genes with synonymous mutations were found and 33 
nonsynonymous mutations (pncA+) were detected. One test result was not interpretable; this 
inconclusive isolate was classified as PZA-susceptible MDR-TB and grouped with the negative 
results (see Statistical analysis). 
The molecular algorithm based on finding a pncA mutation in a population of patients 
with an rpoB mutation (pncA added to rpoB mutation) detected 30 of the 31 PZA-resistant 
MDR-TB patients (Figure 1). Three patients would be incorrectly labelled as PZA-resistant 
MDR-TB. One of the isolates from these patients proved to be isoniazid and PZA-resistant 
but rifampicin susceptible. This isolate carried a T deletion at a position 12 bp downstream 
of the pncA gene and a Leu511Pro combined with a Met515Leu mutation in the rpoB gene. 
The two other isolates, carrying a Val155Met and an Asp129Asn mutation in the pncA gene, 
were classified as MDR-TB, but were repeatedly PZA-susceptible in phenotypic testing. One 
patient with a PZA-resistant MDR-TB isolate carried a wild type pncA gene and would be 
incorrectly labelled as pyrazinamide-susceptible MDR-TB (Figure 1). Overall, the sensitivity of 
the index test (pncA added to rpoB mutation) for detecting pyrazinamide-resistant MDR-TB 
was 96.8%, the specificity was 94.2%, the positive predictive value was 90.9%, the negative 
predictive value was 98.0%, the positive likelihood was 16.8 and the negative likelihood was 
0.03 (Table 3). 
Table 3  
Diagnostic accuracy of pncA sequencing added to rpoB mutation analysis for diagnosing  
pyrazinamide-resistant MDR-TB
estimate 95%-CI
sensitivity 96.8 83.8-99.4
Specificity 94.2 84.4-98.0
positive predictive value 90.9 76.4-96.9
negative predictive value 98.0 89.5-99.7
positive likelihood ratio 16.8 8.7-32.3
negative likelihood ratio 0.03 0.005-0.2
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DIsCussIon
In this study we have found that pncA sequencing added to rpoB mutation analysis can 
accurately identify PZA-resistant MDR-TB. We showed that sequencing the pncA gene in M. 
tuberculosis isolates with an rpoB mutation had a sensitivity of 97% and specificity of 94% to 
detect pyrazinamide-resistant MDR-TB (Table 3). The rigorous DST testing to pyrazinamide and 
our set up as a diagnostic accuracy study according to STARD guidelines strengthens the validity 
of these results. Moreover, our results add to the growing evidence that screening for mutations 
in the pncA gene can be used as a solid proxy for pyrazinamide resistance in MDR-TB settings.4 
In the present study, we wanted to set up a pragmatic diagnostic algorithm for high-burden 
MDR-TB settings, where screening for MDR-TB is preferably performed using rpoB gene 
mutation analysis.1 That is why this algorithm is different from our previously published 
algorithm, which is more suitable for diagnosing pyrazinamide resistance in low-burden 
MDR-TB and PZA-resistant settings.6 These two diagnostic algorithms together may help 
microbiologists in standardizing pyrazinamide resistance testing in low-burden as well as in 
high-burden MDR-TB settings. 
In view of the central role of pyrazinamide in novel (MDR-)TB treatment regimens, such 
as in the NC-002 and NC-003 trials (www.tballiance.org), some authors have suggested 
stratifying MDR-TB according to PZA susceptibility.5 As such, we propose to perform pncA 
sequencing in every isolate with a mutation in the rpoB gene to rapidly and accurately detect 
pyrazinamide-resistant MDR-TB.5 Anecdotal evidence suggest that such strategy, when 
performed on direct sputum samples, may give accurate results within days.13
Other researchers have found lower proportions (between 72 and 88%) of nonsynonymous 
mutations in PZA-resistant strains highlighting the risk of false susceptibility, e.g. 
pyrazinamide resistance in wild-type pncA.6,14,15 However, contrary to our study, these studies 
were not designed as diagnostic accuracy studies, did not re-test isolates in the MGIT 960 
system, or were not performed in an MDR-TB population.5 The occurrence of mutations in 
other genes, such as in the recently described rpsA gene and panD gene, could also explain 
why others found higher number of PZA resistant isolates without pncA mutations.16,17 In 
the present study, we did not systematically test for these mutations, since we rarely found 
PZA-resistant isolates with wild-type pncA and the clinical significance of these alternative 
mutations in routine pyrazinamide diagnostics is yet to be determined.18
Contrary to our expectations, we noted that mutations in the rpoB gene were not a perfect 
predictor for MDR-TB (Figure 1). On the one hand, we saw some rifampicin monoresistant 
isolates. This could be caused by the fact that our rpoB+ patients were drawn from a 
population with low levels of rifampicin resistance. It has been shown previously that in 
such situations rpoB mutations have a low positive predictive value for detecting MDR-
TB.19 On the other hand, we noted that around 10% of rpoB mutations recorded in this study 
gave rise to a rifampicin-susceptible phenotype in the MGIT system. These rpoB mutations 
occured mostly at specific positions of the rpoB gene (Table 2) that have been associated with 
discordant results for rifampicin in the MGIT 960 system.20 These specific mutations probably 
give rise to MICs for rifampicin that lay around its break point concentration, thereby leading 
to so-called low-level, or intermediate, rifampicin-resistant strains.20,21 This marks a flaw 
inherent to determining rifampicin susceptibility by rapid phenotypic DST assays, testing 
only at the breakpoint concentration. This is an important finding that poses a therapeutic 
challenge because the mutations that yield low-level resistance have been associated with 
treatment failure and relapse.22,23 
In the present study, we presupposed that all pncA mutations were in fact resistance-
determining mutations. And indeed, most of the pncA mutations seen in this study (Table 2) 
are in agreement with the resistance-determining mutations found in the DreamDB database 
(http://www.tbdreamdb.com, accessed February 17, 2014), seven of which are listed as high 
confidence for being resistance-determining.24 Seven mutations have not been described 
previously and two mutations –Thr168Pro and Met175Ile- were found in other publications 
(Table 2).25,26 The Met175Ile mutation has previously been associated with both susceptible 
and resistant pyrazinamide strains.25 Stoffels and co-workers have shown that these type of 
mutations encode for low-level pyrazinamide resistance,25 explaining why they might not 
be adequately detected using the MGIT 960 system. Low-level pyrazinamide resistance not 
detected by the MGIT system might also explain why we found two non-synonymous pncA 
mutations in pyrazinamide-susceptible strains (Table 2). On the other hand, these two might 
not be resistance-determining mutations; pncA mutant, but pyrazinamide susceptible isolates 
are occasionally seen.
Many factors interplay in a real-life diagnostic testing strategy and the present study should be 
cautiously interpreted as such owing to its design. First, some bias may have been introduced 
by the retrospective nature of our study using archived samples. Second, though the rigorous 
DST for pyrazinamide did strengthen the validity of our MGIT 960 results, such strategy 
is probably not feasible in routine diagnostics. Third, we performed indirect molecular 
DST using M. tuberculosis cultures, whereas in practice we would have prefered to perform 
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the molecular analysis directly on sputum samples. Future studies should examine the 
performance of this technique in programmatic settings.  
In conclusion, we found that diagnosing pyrazinamide-resistant MDR-TB by rapid molecular 
assays is highly accurate. We therefore propose to include pncA sequencing for every M. 
tuberculosis isolate with a mutation in the rpoB gene. This makes it possible to stratify MDR-
TB according to pyrazinamide susceptibility, thereby paving the way for the urgently needed 
treatment efficacy studies within this population.
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ChapTer sIX
Accuracy of genotypic and phenotypic methods 
for second-line drug susceptibility testing
adapted from:
Van Ingen J., Simons S., de Zwaan R., van der Laan T., Kamst-van Agterveld M., Boeree M. 
J., van Soolingen D. Comparative study on genotypic and phenotypic second-line drug 
resistance testing of Mycobacterium tuberculosis complex isolates.
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absTraCT
Background: The Mycobacteria Growth Indicator Tube (MGIT 960) automated liquid 
medium testing method is becoming the international gold standard for second-line 
drug susceptibility testing of multidrug- and extensively drug-resistant Mycobacterium 
tuberculosis complex isolates. 
Design: We performed a comparative study of the current gold standard in the Netherlands, 
the Middlebrook 7H10 agar dilution method, the MGIT 960 system, and the GenoType 
MTBDRsl genotypic method for rapid screening of aminoglycoside and fluoroquinolone 
resistance. We selected 28 clinical multidrug- and extensively drug-resistant M. tuberculosis 
complex strains and M. tuberculosis H37Rv. We included amikacin, capreomycin, 
moxifloxacin, prothionamide, clofazimine, linezolid, and rifabutin in the phenotypic test 
panels. For prothionamide and moxifloxacin, the various proposed breakpoint concentrations 
were tested by using the MGIT 960 method. 
Results: The MGIT 960 method yielded results 10 days faster than the agar dilution method. 
For amikacin, capreomycin, linezolid, and rifabutin, results obtained by all methods were 
fully concordant. Applying a breakpoint of 0.5 mg/l for moxifloxacin led to results concordant 
with those of both the agar dilution method and the genotypic method. For prothionamide, 
concordance was noted only at the lowest and highest MICs. The phenotypic methods yielded 
largely identical results, except for those for prothionamide. 
Conclusions: Our study supports the following breakpoints for the MGIT 960 method: 
1 mg/l for amikacin, linezolid, and clofazimine, 0.5 mg/l for moxifloxacin and rifabutin, 
and 2.5 mg/l for capreomycin. No breakpoint was previously proposed for clofazimine. For 
prothionamide, a division into susceptible, intermediate, and resistant seems warranted, 
although the boundaries require additional study. The genotypic assay proved a reliable and 
rapid method for predicting aminoglycoside and fluoroquinolone resistance.
InTroDuCTIon
The emergence of multidrug-resistant tuberculosis (MDR-TB) in the 1990s, and more 
recently, extensively drug resistant tuberculosis (XDR-TB), has revealed the need for new 
drugs and alternative, second-line treatment regimens. Many of these second-line drugs are 
either old drugs that had not been frequently used because of side effects or unproven efficacy 
or newer drugs intended primarily for treatment of other infections.1 Their use necessitated 
an evaluation of drug susceptibility testing (DST) and a determination of the critical 
concentrations of these alternative drugs.
A variety of techniques is now available for second-line DST, of which the Mycobacteria 
Growth Indicator Tube automated liquid culture system (MGIT 960) is probably the most 
used and best validated at this moment.2 The latest addition to second-line DST are genotypic 
methods, which detect mutations in the gyrA gene of Mycobacterium tuberculosis that are 
associated with fluoroquinolone resistance and mutations in the rrs operon that are associated 
with resistance to capreomycin and the aminoglycosides.1,3-5 
Despite the arrival of these novel tools, many uncertainties remain. Not all methods have been 
evaluated in comparative studies. Moreover, the critical concentrations for resistance to several 
second- and third-line drugs, including moxifloxacin and prothionamide, remain the subject 
of debate.2,6,7
In the Netherlands, the Middlebrook 7H10 agar dilution method has been used for second-
line DST for 2 decades.8 In order to comply with international standardization requirements, 
a switch to the MGIT960 method has been initiated. In this study, we have compared the 
results of the MGIT960 method and the GenoType MTBDRsl assay, a commercially available 
genotypic second-line DST method, to our reference method, the Middlebrook 7H10 agar 
dilution method. For the MGIT960 method, we tested the various critical concentrations 
published for prothionamide and moxifloxacin but also included clofazimine in our drug 
panel. For the latter drug, which has become increasingly important in the treatment of MDR 
and XDR-TB, no in vitro DST data for the MGIT960 method were available.
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MaTerIals anD MeThoDs
From our laboratory database, we selected 28 multidrug-resistant clinical isolates (26 M. 
tuberculosis and 2 Mycobacterium bovis) and the M. tuberculosis H37Rv reference strain. 
Isolates were nonrandomly selected to include those previously designated susceptible and 
resistant to each of the drugs included in the test panel, except linezolid, for which no resistant 
strains are available. All strains were identified by a GenoType MTBC assay (Hain Lifescience, 
Nehren, Germany).
We performed DST using the 25-well Middlebrook 7H10 agar dilution method as previously 
described,8 the automated MGIT960 method with the TBeXist application and EpiCenter 
software package (BD Bioscience, Erebodegem, Belgium),9 and the genotypic GenoType 
MTBDRsl reverse line blot methodology (Hain Lifescience, Nehren, Germany).4,5 This 
molecular test detects mutations in the rrs (16S) gene that give rise to amikacin, kanamycin, 
and capreomycin resistance, as well as gyrA gene mutations that lead to fluoroquinolone 
resistance. The agar dilution method was considered the gold standard, and the selection of 
strains was based on previous results obtained by this method.
The applied drug concentrations and breakpoints, based on previous publications,2,6-8,10 are 
depicted in Table 1. For the agar dilution method, a MIC equal to the breakpoint concentration 
is reported as susceptible; plates were read after 4, 7, 10, and 14 days of incubation and on each 
working day thereafter. For the MGIT 960 method, growth at the breakpoint concentration is 
considered resistant; drug-containing tubes were read at the moment the growth control was 
signaled positive on the MGIT 960 system. Research was conducted in a blinded manner with 
respect to previous test results and to results obtained by the other methods in this study.
Table 1 
Drug concentrations and breakpoints evaluated in this study
Drug Concentration(s) evaluated (in mg/l)a,b
7h10 MGIT960
amikacin 1, 2, 5, 10, 20 1
Capreomycin 2, 5, 10, 20, 40 2.5
prothionamide 1, 2, 5, 10, 20 2.5, 5
Moxifloxacin 0.125, 0.25, 0.5, 1, 2 0.125, 0.25, 0.5, 1
linezolid 0.125, 0.25, 0.5, 1, 2 0.25, 0.5, 1
rifabutin 0.2, 0.5, 01, 2, 5 0.5
Clofazimine 0.5, 1, 2, 5 0.125, 0.25, 0.5, 1, 2
a boldface type indicates the breakpoint concentration (cut-off point for resistance).2,6-8,10 
b 7H10, Middlebrook 7H10 agar dilution; MGIT 960, mycobacteria growth indicator tube. 
resulTs
The turn-around-time of the MGIT 960 method is substantially shorter than that of the agar 
dilution method; after a mean of 8 days, the growth control tubes were positive (187.8 h; 
standard deviation [SD], 58.3 h) versus a mean duration of 18 days (SD, 3 days) for the agar 
dilution method (P < 0.01).
The DST results for amikacin, capreomycin, linezolid, and rifabutin are presented in Table 2. 
Phenotypic DST results for rifabutin, linezolid, and amikacin were fully concordant between 
the two methods. For capreomycin, 97% concordance was noted; one strain was borderline 
susceptible (MIC, 10 mg/l) when tested by the agar dilution method, but resistant (MIC, >2.5 
mg/l) when tested by the MGIT 960 method (Table 2) (sensitivity, 95%; specificity, 100%); the 
genotypic assay detected an rrs gene mutation, which resolves this issue in favour of the MGIT 
960 result. Complete cross-resistance between amikacin and capreomycin was noted when 
the MGIT method was used; there was 97% cross-resistance when the agar dilution method 
was used.
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Table 2
Phenotypical drug susceptibility testing results for amikacin, capreomycin, rifabutin, and linezolida
Drug 7h10 result  
(no. of isolates)
no. of isolates with indicated MGIT 
960 result
Concordance (%)
s r
amikacin S (21) 21 0 100
R (8) 0 8
Capreomycin S (22) 21 1b 97
R (7) 0 7
rifabutin S (14) 14 0 100
R (15) 0 15
linezolid S (29) 29 0 100
a  s, susceptible; r, resistant; 7H10, Middlebrook 7H10 agar dilution method; MGIT 960, mycobacteria growth  
indicator tube.
b  This strain harboured the A1401G rrs mutation, favouring the MGIT 960 result and a “resistant” designation.
The results for moxifloxacin are presented in Table 3. For moxifloxacin, the use of the 0.125-
mg/l breakpoint concentration for the MGIT 960 method led to one false-resistance result, 
yielding a 97% concordance (sensitivity, 95%; specificity, 100%); the use of the 1.0-mg/l 
breakpoint led to two false-susceptibility results (93% concordance; sensitivity, 100%; 
specificity, 71%). Applying the 0.5-mg/l breakpoint, complete agreement was noted between 
results obtained by the MGIT 960 and agar dilution methods.
Table 3
Distribution of moxifloxacin MICs determined by two phenotypic methodsa
7H10 MIC of moxifloxacin (mg/l) no. of isolates with indicated MGIT 960 MIC (mg/l)
≤ 0.125 0.25 0.5 1 > 1
≤0.125 14 1 0 0 0
0.25 4 0 0 0 0
0.5 3 0 0 0 0
1 0 0 0 0 0
2 0 0 0 1 2
>2 0 0 0 1 3
a  Twenty-nine isolates were tested. Italics indicate the previously published breakpoint concentration and cut-off for 
resistance. boldface indicates the proposed breakpoint stemming from the current study, 0.5 mg/l for moxifloxacin 
(MGIT 960). 7H10, Middlebrook 7H10 agar dilution method; MGIT 960, mycobacteria growth indicator tube.
The agreement between both phenotypical DST methods was low in prothionamide testing 
(Table 4). Applying the 2.5-mg/l breakpoint for the MGIT 960 method led to six false-
resistance results and one false-susceptibility result (76% concordance; sensitivity, 73%; 
specificity, 86%; positive predictive value [PPV], 94%; negative predictive value [NPV], 50%). 
When applying the 5-mg/l breakpoint, three false resistances and one false susceptibility 
were noted (86% concordance; sensitivity, 86%; specificity, 86%; PPV, 95%; NPV, 67%). From 
these results, it is clear that at the lowest MICs (≤2 [7H10]/≤2.5 mg/l [MGIT 960]) and highest 
MICs (>10 [7H10]/ >5 mg/l [MGIT 960]), concordance is the highest for the two phenotypic 
methods (Table 4).
Table 4
Distribution of prothionamide MICs determined by two phenotypic methods
7h10 MIC of prothionamide  
(mg/l) (no. of strains)
no. of isolates with indicated MGIT 960 MIC (mg/l)a,b
≤ 2.5 > 2.5 and ≤ 5 > 5
<1 (11) 11 0 0
2 (3) 2 1 0
5 (8) 3 2 3
10 (4) 1 0 3
>20 (3) 0 0 3
a  Twenty-nine isolates were tested. Italics indicate the previously published breakpoint concentration and cutoff for 
resistance. boldface indicates proposed breakpoints stemming from the current study; MICs of ≤ 2 (7H10) or ≤ 2.5 
(MGIT 960) mg/l indicate prothionamide susceptibility, MICs of > 10 (7H10) or > 5 (MGIT 960) mg/l indicate resis-
tance, and those in between indicate intermediate susceptibility. 
b  7H10, Middlebrook 7H10 agar dilution method; MGIT 960, mycobacteria growth indicator tube.
All 29 strains proved susceptible to clofazimine by the 7H10 agar dilution method. By the 
MGIT 960 method, two strains were found to be resistant to 0.25 mg/l of clofazimine 
(i.e., a MIC of 0.5 mg/l); all others proved susceptible to this concentration or the lower 
concentrations (Table 5). From these data, a MIC90 of 0.5 mg/l for the agar dilution method can 
be calculated; for the MGIT960 method, the MIC90 is 0.25 mg/l.
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Table 5 
Distribution of clofazimine MICs determined by two phenotypic methods
7h10 MIC of clofazimine (mg/l) no. of isolates with indicated MGIT 960 MIC (mg/l)a,b
≤ 0.125 0.25 0.5 1 2
≤ 0.5 13 11 2 0 0
1 0 3 0 0 0
2 0 0 0 0 0
5 0 0 0 0 0
a  Twenty-nine isolates were tested. Italics indicate the previously published breakpoint concentration and cut-off for 
resistance. boldface indicates the proposed breakpoint stemming from the current study, 1 mg/l for clofazimine 
(MGIT 960). 
b  7H10, Middlebrook 7H10 agar dilution method; MGIT 960, mycobacteria growth indicator tube.
The MTBDRsl assay revealed rrs mutations in eight strains (6 M. tuberculosis, 2 M. bovis) 
and gyrA mutations in seven strains (5 M. tuberculosis, 2 M. bovis). Five strains harboured 
the A1401G rrs (16S rRNA) gene mutation, and three harbored a C1402T mutation (1 M. 
tuberculosis, 2 M. bovis). Hybridization with the probe for the A1401G mutation was generally 
weak. All isolates with rrs mutations proved amikacin and capreomycin resistant, except for 
one strain with an A1401G rrs mutation that proved amikacin resistant by 7H10 agar dilution 
and MGIT960 testing but had a MIC of 10 mg/l for capreomycin, i.e., at the breakpoint, by the 
7H10 agar dilution method. No false-positive or false-negative results were recorded.
Among the seven strains with gyrA mutations, one harboured an A90V mutation, three 
harboured an S91P mutation (including the 2 M. bovis strains), and one had the D94G 
mutation. Two strains were found to have multiple mutations; one had A90V and D94A 
mutations, and the other had A90V, S91P, and D94N mutations. For both, one mutant probe 
hybridized well and yielded a high-intensity band, whereas the others were weak. In 3 out 
of 8 strains (38%) with mutations in gyrA, wild-type sequences were also detected by the 
MTBDRsl assay. All seven isolates with mutations in gyrA proved moxifloxacin resistant by 
the 7H10 agar dilution method; no false-positive or false-negative results were recorded. All 
seven isolates with gyrA gene mutations had MICs above 0.5 mg/l for moxifloxacin when 
tested by the MGIT 960 method.
DIsCussIon
The results of second-line DST for M. tuberculosis complex bacteria obtained by the 7H10 agar 
dilution method and MGIT 960 method are largely similar. The much shorter turn-around-
time for the MGIT 960 method (mean, 8 versus 18 days) is a major advantage over that of the 
previous standard, the 7H10 agar dilution method. Moreover, the reading in the MGIT system 
is done automatically, which is preferred over the reading by eye in the classical 7H10 agar 
method. Fast yet robust laboratory results are of paramount importance to guide the choice of 
drugs in MDR- and XDR-TB treatment. Before confidently switching to MGIT 960 as the gold 
standard for second-line DST, the uncertainties involving moxifloxacin and prothionamide 
breakpoints must be resolved.
Of all quinolones, moxifloxacin is considered the most promising antituberculosis drug.1,11,12 
As a result, in vitro DST for this drug has become an important issue. However, the 
breakpoint concentration for the MGIT method is still a subject of debate, with published 
breakpoints ranging from 0.125 mg/l6 to 0.5 mg/l13,14 and 1.0 mg/l.10 Our comparison of the 
two phenotypic methods and the genotypic method supports the choice of 0.5 mg/l as the 
breakpoint. One strain without detectable gyrA mutations proved resistant to 0.125 mg/l of 
moxifloxacin, a previously proposed breakpoint;6 false-resistance results are major errors and 
could lead to unwarranted diagnoses of XDR-TB and unnecessary restrictions in the selection 
of active drugs for individual treatment regimens. Two strains with gyrA mutations grew at 
0.125, 0.25, and 0.5 mg/l but not at 1 mg/l. Here, the 1.0-mg/l breakpoint10 would have led 
to false-susceptibility results; this can lead to the inclusion of presumably inactive drugs in 
treatment regimens, with serious consequences, and counts as a very major error.6
For moxifloxacin, the 0.5-mg/l MGIT 960 breakpoint concentration seems to correlate well 
with the drug's bioavailability. In a recent study, the regular 400-mg once-daily dosage of 
moxifloxacin led to maximum serum concentrations of 4.7 mg/l, an area under the curve 
(AUC) of 48.2 mg·h/liter, and trough concentrations (24 h after intake) of 0.78 mg/l.11 
The AUC/MIC ratio best describes the activity of moxifloxacin against M. tuberculosis3,15 
and should be >100 for optimal bactericidal activity, although this is rarely reached in TB 
treatment.13 Applying the 1.0-mg/l (7H10) and 0.5-mg/l breakpoints (MGIT) to designate 
susceptible isolates, the MIC90 was 0.5 (7H10) or 0.25 (MGIT) mg/l, leading to an AUC/MIC90 
of 96.4 or 192.8, both compatible with substantial clinical activity.
Based on the suggested breakpoint concentrations for prothionamide, MGIT 960 test 
results compare poorly with those of the agar dilution method, at 76 to 86% concordance. 
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This discordance is not a novel observation, although its extent is larger than seen in 
previous studies. Two previous extensive studies noted more major and very major errors 
in prothionamide testing than for any other second-line drug.2,6 Owing to the inclusion of 
many susceptible strains, both studies still showed 96% and 97% percent agreement when 
applying the 2.5- and 5.0-mg/l breakpoints for the MGIT 960 method, compared to results 
for the resistance ratio method6 or BACTEC 460 radiometric method.2 In our study, the 
concordance was highest at the lowest and highest MICs, which suggests that one breakpoint 
defining susceptibility and resistance may not be adequate for prothionamide. A division into 
susceptible, intermediate, and resistant may be preferable, at least if there are pharmacokinetic 
and clinical consequences. The existence of low-level resistance has also been suggested by 
previous investigators, on the basis of discrepancies in drug susceptibility testing.2,9 Larger 
studies are needed to define the suitability of this division and its MIC breakpoints as well as 
the genomic mutations underlying the different degrees of resistance.9 On the basis of our 
data, isolates with MICs of ≤ 2 (7H10) or ≤ 2.5 (MGIT) mg/l should be considered susceptible, 
those with MICs of >10 (7H10) or >5 (MGIT) mg/l should be considered resistant, and all 
those in between should be considered intermediate susceptible. For the intermediate group, 
pharmacokinetic and pharmacodynamic studies would be needed to determine the possible 
efficacy of prothionamide treatment.
Based on the MIC90 of 0.25 mg/l for clofazimine (Table 5), we propose a breakpoint 
concentration of 1 mg/l for the MGIT960 method, although the stability of clofazimine in 7H9 
medium warrants separate investigation. However, the mechanism of action of clofazimine 
against M. tuberculosis remains uncertain,1 and the difficulties in isolating clofazimine-
resistant strains16 raise a question about the existence of clofazimine resistance. In fact, the 
only isolate we previously found to be clofazimine resistant8 was intentionally included in 
this study and now proved susceptible by both phenotypic methods, rendering the previous 
observation most likely a laboratory mistake. The mutations needed to acquire clofazimine 
resistance may have an impact on the viability of M. tuberculosis.16 For nontuberculous 
mycobacteria, clofazimine resistance exists, mainly among rapid growers, though its 
underlying mechanism is not known.17
The molecular assay proved highly reliable in detecting amikacin, capreomycin, and 
moxifloxacin resistance. All rrs mutations predicted amikacin and/or capreomycin resistance. 
Therefore, the positive predictive value of the genotypic tests may be considered very high. 
One strain with a “MUT1” (A1401G) rrs mutation still tested capreomycin susceptible, albeit 
borderline, by the 7H10 agar dilution method. However, according to a previous study, this 
mutation induces capreomycin resistance.18 In contrast, for three strains, no hybridization 
with the wild-type probe was noted in the absence of MUT1 (i.e., the A1401G mutation) probe 
hybridization. This specific result indicates the presence of the C1402T mutation,4 which is 
supposed to result in amikacin susceptibility and capreomycin resistance.18 Our three strains 
all proved to be cross-resistant to both drugs; Hillemann and co-workers also noted this 
phenomenon for one strain in their study of the MTBDRsl assay's performance.5 Since the 
hybridization of the MUT1 probe was generally weak, A1401G mutations may have potentially 
been misinterpreted as C1402T mutations.
For moxifloxacin resistance, the obtained MTBDRsl results were fully concordant with the 
MGIT960 results if the 0.5-mg/l breakpoint was applied. In fact, the molecular analysis 
provides further support for this breakpoint. Complete concordance with the 7H10 agar 
dilution was noted. Multiple mutations were found for two strains. Interestingly, in three out 
of eight strains with mutations in gyrA, wild-type sequences were also detected. This suggests 
that in these isolates, both wild-type (susceptible) and mutant (resistant) bacterial populations 
are present, in a ratio sufficient to allow hybridization of the wild-type and mutant probes. 
These results were also frequently found (21.9%) in the study by Hillemann and co-workers.5 
This heteroresistance may result from the emergence of resistant subpopulations or infection 
by multiple strains, as has been noted for isoniazid and rifampin.19
While the MTBDRsl assay includes probes for embB gene mutation analysis, we decided not to 
compare these results with ethambutol results for the phenotypic methods, as low sensitivity of 
the molecular system has already been demonstrated5 and ethambutol is not a second-line drug.
The intricacies of second-line DST by phenotypic methods and their importance in clinical 
care underline the need for quality control efforts, both internal and external. The use of 
control strains may be preferable to minimize intertest variance; external quality control 
schemes are already in existence for second-line DST to ensure interlaboratory reproducibility.
In summary, the 7H10 agar dilution and MGIT 960 phenotypical second-line DST methods 
for M. tuberculosis yielded largely identical results, except for those for prothionamide. For 
moxifloxacin and clofazimine, we propose 0.5 mg/l and 1 mg/l, respectively, as breakpoint 
concentrations for the MGIT 960 method. For amikacin, capreomycin, rifabutin, and 
linezolid, we support the 1.0-, 2.5-, 0.5-, and 1-mg/l breakpoint concentrations suggested 
previously.2,6 The MGIT 960 method has a much shorter turn-around-time than the 
conventional 7H10 agar method, which is essential for the timely optimization of patient 
treatment regimens. Here, the MTBDRsl molecular assay proved to be a reliable method for 
predicting aminoglycoside and fluoroquinolone resistance and thus for the rapid screening of 
(MDR-)TB strains for possible extensive drug resistance.
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absTraCT
Background: The performance of molecular drug susceptibility tests in countries with low 
prevalence of drug resistance, such as the Netherlands, has not been adequately studied. 
Objective: To evaluate the diagnostic accuracy of the GenoType® MTBDRplus and the 
MTBDRsl test to detect resistance to first-line and second-line antituberculosis drugs in the 
context of a nationwide screening program in the Netherlands. 
Results: The MTBDRplus assay had a sensitivity, specificity, positive and negative predictive 
value of 100%, 99%, 80% and 100% for detecting rifampicin resistance. Sensitivity, specificity, 
positive and negative predictive value of either a katG or inhA mutation for detecting isoniazid 
resistance was 88%, 100%, 100% and 99%. The MTBDRsl assay had a sensitivity, specificity, 
positive and negative predictive value of 100%, 99%, 83%, and 100% for detecting moxifloxacin 
resistance. This was 62%, 71%, 58% and 74% for detecting ethambutol resistance. Sensitivity, 
specificity, positive and negative predictive value was 86%, 99%, 86%, and 99% for detecting 
amikacin resistance and 50%, 96%, 71%, and 91% for detecting capreomycin resistance. 
Conclusion: The MTBDRplus and MTBDRsl assay may aid in decision making in tuberculosis 
treatment in low-level drug resistance settings and should preferably be used to exclude 
resistance. 
InTroDuCTIon
Molecular tests that detect specific resistance-determining mutations in the M. tuberculosis 
genome have aided in a rapid diagnosis of drug-resistant tuberculosis (TB).1 Examples of such 
rapid drug susceptibility tests (DST) are the GenoType® MTBDRplus and the Xpert® MTB/
RIF for the detection of multidrug-resistant TB (MDR-TB) and the GenoType® MTBDRsl 
for the detection of resistance to second-line antituberculosis drugs and ethambutol.2,3 
Implementation of these tests has provided substantial patient and programmatic benefits 
for diagnosing MDR-TB in high-burden settings.4 As a result, recent WHO guidelines have 
recommended that the Xpert® MTB/RIF should be used as the initial diagnostic test in adults 
suspected of having MDR-TB in high-burden settings.5
There are only a few studies on the performance of these tests in countries with low levels of 
drug resistance however.2,6,7 Differences between high-burden and low-burden countries are 
important to appreciate the operational characteristics of these tests. These differences are the 
lower positive predictive value,2 the higher number of patients with paucibacillary disease6 
and differences in logistics and resources.6 There is therefore a need to generate more evidence 
on diagnostic accuracy of these molecular DST in low-incidence, high-resource countries. 
The Netherlands is such a low-level drug resistance country with 1% of new TB cases and 2% 
of previously treated cases being MDR-TB.8 The national tuberculosis reference laboratory 
receives all M. tuberculosis cultures from the Netherlands for phenotypic drug-susceptibility 
testing. The GenoType® MTBDRplus and the MTBDRsl test have been routinely used since 
2007 and 2009 for the early detection of drug-resistant tuberculosis. The goal of the present 
study was to assess diagnostic accuracy of the GenoType® MTBDRplus and the MTBDRsl 
tests in the Netherlands. We therefore performed a retrospectively study to compare 
these two molecular tests with phenotypic drug resistance results to first-line and second-
line antituberculosis drugs in the context of routine, non-trial diagnostics provided by a 
nationwide laboratory service.
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MaTerIals anD MeThoDs
sample collection
This study was performed at the National Tuberculosis Reference Laboratory, which serves 
as the national referral laboratory for drug susceptibility testing (DST) of Mycobacterium 
tuberculosis complex isolates for the Netherlands. We retrospectively identified all 
Mycobacterium tuberculosis complex isolates that were sent to our laboratory for DST from 
2007 to 2012. The GenoType® MTBC assay (Hain Lifescience GmbH, Nehren, Germany) was 
used for (sub) species identification. 
phenotypic drug susceptibility testing
Drug susceptibility testing to first-line antituberculosis drugs was carried out using the 
Mycobacteria Growth Indicator Tube (MGIT) 960 system (BD Bioscience, Erebodegem, 
Belgium) using break point concentrations of 1.0 mg/l (Streptomycin), 0.1 mg/l (isoniazid), 
1.0 mg/l (rifampicin), 5.0 mg/l (ethambutol) and 100 mg/l (pyrazinamide). Drug 
susceptibility testing to second-line antituberculosis drugs was performed in multidrug-
resistant isolates using either a Middlebrook 7H10 agar dilution method9 using break point 
concentrations of 1.0 mg/l (moxifloxacin), 10.0 mg/l (capreomycin), 5.0 mg/l (amikacin) or 
the MGIT 960 system using break point concentrations of 0.5 mg/l (moxifloxacin), 2.5 mg/l 
(capreomycin) and 1.0 mg/l (amikacin).10 
Molecular DsT
We used the GenoType® MTBDRplus assay (Hain Lifesciences, Nehren, Germany) to screen 
for mutations in the rpoB, inhA and the katG genes.11 The GenoType® MTBDRsl assay was 
used in every MDR M. tuberculosis isolate to screen for mutations in the gyrA, embB and the 
rrs genes.12 Some of these results have been previously published.10,13
analysis
The primary analysis was the diagnostic accuracy of the MTBDRplus and MTBDRsl assay to 
detect phenotypic drug resistance to rifampicin (rpoB), isoniazid (inhA/katG), ethambutol 
(embB), moxifloxacin (gyrA), capreomycin (rrs) or amikacin (rrs). One isolate per patient 
was used. Diagnostic accuracy was expressed as sensitivity (Se), specificity (Sp), positive 
predictive value (PPV), and negative predictive value (NPV) using 2x2 contingency tables and 
OpenEpi software version 2.3.1; [http://www.OpenEpi.com]). 
The Netherlands Tuberculosis Registry provided data on patient characteristics after approval 
by the registry committee. These data were matched with microbiological results on the 
basis of a unique isolate number. The final dataset consisted of anonymous data. Ethical 
approval was therefore not required. A multivariate logistic regression analysis with MDR-
TB as the independent variable and age < 45 year, sex, prior treatment and country-of-origin 
(foreign-born) as dependent variables was performed to identify risk groups for MDR-TB.14,15 
Threshold for significance (P-value) was set at 0.05. Precision of the estimates was reported 
using 95% confidence intervals (95% CI). We used SPSS version 20.0 (IBM corporation, 
Armonk, NY) for all statistical analysis.
Two nationwide screening strategies have been applied during the study period for the 
MTBDRplus assay: routine testing of all new isolates (2009 and 2010) and testing upon request 
by submitting laboratories (2007, 2008, 2011 and 2012). We determined the potential clinical 
relevance of these two screening strategies by comparing the diagnostic accuracy. Moreover, 
we calculated whether screening high-risk groups would improve accuracy by defining 
a hypothetical cohort with high-risk patients (defined as age < 45 years, prior treatment 
or foreign-born). Accuracy of the MTBDRplus assay in this hypothetical cohort was then 
compared with the routine screening strategy.
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resulTs
study population
Of the 5,305 isolates sent to the laboratory for DST, a comparison between the MTBDRplus 
assay and phenotypic DST was possible in 2,649 (Figure 1). A comparison between the 
MTBDRsl assay and phenotypic DST to second-line antituberculosis drugs was possible in 74 
cases, except for DST to capreomycin, which was performed in 65 cases only. 
Characteristics of the study population are shown in Table 1. Median age of the 2,649 cases was 
37 years and the majority was male. Phenotypic MDR-TB was seen in 74 cases (3%). MDR-TB 
cases were younger, were more often female and foreign-born (Table 1). Age under 45 years 
(OR 7.2, 95%-CI: 2.6-20.2), prior treatment (OR 5.0, 95%-CI: 2.4-10.4), foreign-born (OR 4.3, 
95%-CI: 1.3-14.0) and female sex (OR 2.2, 95%-CI: 1.3-3.6) were all risk factors for MDR-TB.
figure 1
Flow chart of M. tuberculosis complex samples sent to the National Institute for Public Health and 
the Environment (RIVM) for molecular analysis with either the MTBDRplus assay or the MTBDRsl assay 
(2007-12)
Table 1 
Characteristics of the study population
all patients  
(n = 2,649)
MDr-Tb patients  
(n=74)
Demographics
Age in years (median, IQR) 37 [27, 55] 28 [23, 33]
Sex (% males) 59% 43%
Foreign born (%) 68% 82%
From high-burden MDR-TB country (%) 18% 32%
Prior TB treatment (%) 5% 14%
Pulmonary TB (%) 55% 72%
MTB species (%)
M tuberculosis 95% 100%
M bovis (+ BCG) 4% -
M africanum 1% -
Resistance profile (% of resistant isolates)
Rifampicin 3% 100%
Isoniazid 12% 100%
Ethambutol 1% 39%
Pyrazinamide 5%a 42%
Streptomycin 8% 68%
MDR-TB 3% 100%
Amikacin 10%
Capreomycin 14%a
Moxifloxacin 7%
Pre XDR-TBb <1% 17%
XDR-TB <1% 5%
a  23 isolates were not tested for susceptibility to pyrazinamide and 9 isolates were not tested for susceptibility to 
capreomycin.
b pre-XDR is defined as MDR-TB with either resistant to fluoroquinolones or second-line injectables but not to both. 
Diagnostic accuracy of the MTbDrplus assay
The MTBDRplus assay detected mutations in the rpoB gene of 104 isolates (Table 2), 83 of 
which were phenotypically rifampicin resistant and 74 of which were MDR-TB according to 
phenotypic methods. 
Overall, sensitivity and specificity of the MTBDRplus assay to detect rifampicin resistance 
was 100% (95%-CI: 96-100%) and 99% (95%-CI: 99-100%), respectively (Table 3). Positive 
5,305 isolates sent to 
RIVM for analysis
2,463 excluded:
-no DST (478)
-only DST (1,895)
-only molecular analysis 
(90)
-double isolates (193)
2,738 isolates without 
rpoB mutation
104 isolates with rpoB 
mutation
30 no MDR
74 MDR-TB isolates  
analyzed with  
MDRTBsl assay
2,842 isolates analyzed 
with MTBDRplus
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predictive value was 80% (95%-CI: 71-86%) and negative predictive value 100% (95%-CI: 100-
100%). Sensitivity of an rpoB mutation for detecting phenotypical MDR-TB was 100% (95%-
CI: 96-100%), specificity was 99% (95%-CI: 98-99%), positive predictive value 71% (95%-CI: 
62-79%) and negative predictive value 100% (95%-CI: 100-100%). 
Table 2
Mutations in the rpoB, katG, inhA, gyrA, rrs and embB genes found in the Netherlands using the 
MTBDRplus and the MTBDRsl assay
Gene no. of isolates  
with mutations 
Mutation (no.)
rpoB 104 516Val (1), 526Asp (6), 526Tyr (7), 531Leu (56), Other (34)
katGa 178 S315T1 (176), S315T2 (2)
inhA 117 A-16G (1), C-15T (103), T-8C (5), T-8A (4), other (4)
gyrA 6 94Gly (4), 94Ala (1), 90Val (1)
Rrs 7 A1401G (5), C1401T (2)
embB 31 306Val (17), 306Ile (14)
a  The MTBDRplus assay includes two different katG probes detecting mutations at codons 315 with AGC-ACC (315T1) 
and AGC-ACA (315T2) mutations
Table 3 
Diagnostic accuracy of the MTBDRplus assay for detecting phenotypic drug resistance in  
the Netherlandsa,b
Drug profile rifampicin  
resistant
Isoniazid resistant MDr-Tb
Molecular  
target
rpoB inhA katG Any inhA  
or katG  
mutation
rpoB rpoB with 
any inhA  
or katG  
mutation
Sensitivity 100%  
[96-100%]
36%  
[31-41%]
55%  
[50-61%]
88% 
[84-91%]
100% 
[96-100%]
95% 
[87-98%
Specificity 99%  
[99-100%]
100%  
[100-100%]
100%  
[100-100%]
100%  
[100-100%]
99% 
[98-99%]
100% 
[99-100%]
PPV 80%  
[71-86%]
99%  
[95-100%]
100%  
[98-100%]
100%  
[98-100%]
71% 
[62-79%]
88% 
[79-93%]
NPV 100%  
[100-100%]
92%  
[91-93%]
94%  
[93-95%]
98%  
[98-99%]
100% 
[100-100%]
100% 
[100-
100%]
a Estimates are given as percentages with 95% confidence intervals in brackets
b PPV, positive predictive value; NPV, negative predictive value
The MTBDRplus assay detected 178 mutations in the katG gene and 117 mutations in the inhA 
gene (Table 2). Sensitivity of a katG mutation for detecting isoniazid resistance was 55% (95%-CI: 
50-61%), specificity was 100% (95%-CI: 100-100%), positive predictive value 100% (95%-CI:100-
100%) and negative predictive value 94% (95%-CI: 93-95%) (Table 3). The sensitivity of mutations 
in the inhA gene for detecting isoniazid resistance was poor (36%). Specificity was much better 
leading to a high positive predictive value (100%, 95%-CI: 98-100%). Diagnostic accuracy improved 
when results of the two molecular targets for isoniazid resistance were combined. The sensitivity 
of any mutation in either the katG or inhA gene for detecting isoniazid resistance was 88% (95%-CI: 
84-91%), the specificity 100% (95%-CI: 100-100%), the positive predictive value 100% (95%-CI: 
98-100%), and the negative predictive value 98% (95%-CI: 98-99%).
Diagnostic accuracy of the MTbDrsl assay
The MTBDRsl assay was performed in every MDR-TB case diagnosed in the period 2007-
2012. Mutations in the embB gene were encountered most often, followed by rrs mutations 
and gyrA mutations (42%, 9% and 8%, respectively) (Table 2). The diagnostic accuracy of gyrA 
mutations for detecting moxifloxacin resistance was good (Table 4); sensitivity was 100% 
(95%-CI: 57-100%), specificity was 99% (95%-CI: 92-100%), positive predictive value was 83% 
(95%-CI: 44-97%) and negative predictive value 100% (95%-CI: 95-100%). 
Diagnostic accuracy of the MTBDRsl assay for detecting resistance to second-line injectables is 
shown in Table 4. Sensitivity of an rrs mutation for detecting phenotypic resistance to second-
line injectables was mediocre at best (50% and 86% for capreomycin and amikacin resistance, 
respectively). Specificity was higher, reaching 96% for capreomycin (95%-CI: 88-99%) and 
99% for amikacin (95%-CI: 92-100%). The positive predictive value of an rrs mutation for 
detecting resistance to capreomycin was 71% (95-CI: 36-92%) and the negative predictive 
value was 91% (95%-CI: 91-96%). The positive predictive value or an rrs mutation for detecting 
resistance to amikacin was 86% (95%-CI: 49-97%) and the negative predictive value was 99% 
(95%-CI: 92-100%). 
Diagnostic accuracy of a embB mutation for detecting ethambutol resistance was mediocre 
with a sensitivity of 62% (95%-CI: 44-77%) and a specificity of 71% (95%-CI: 57-82%). The 
positive predictive value was 58% (95%-CI: 41-74%) and the negative predictive value was 74% 
(95%-CI: 60-85%).
Four XDR-TB cases were seen. All these cases could be detected using gyrA mutations as a 
marker for XDR-TB (Table 4). Sensitivity and specificity of a gyrA mutation for detecting 
XDR-TB were 100% (95%-CI: 51-100%) and 97% (95%-CI: 90-99%). Two additional isolates 
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carrying a gyrA mutation were only pre-XDR, lowering positive predictive value of a gyrA 
mutation for XDR-TB to 67% (95%-CI: 30-90%). In contrast, the negative predictive value was 
excellent (100%, 95%-CI: 95-100%). 
Table 4 
Diagnostic accuracy of the MTBDRsl test for detecting phenotypic susceptibility to second-line antitu-
berculosis drugs in the Netherlandsa,b
resistance 
profile
capreomycin amikacin moxifloxacin ethambutol XDr-Tb
Target rrs rrs gyrA embB gyrA rrs
Sensitivity 50%
[24-76%]
86%  
[49-97%]
100%  
[57-100%]
62% 
[44-77%]
100% 
[51-100%]
75% 
[30-95%]
Specificity 96%
[88-99%]
99%  
[92-100%]
99% 
[92-100%]
71%
 [57-82%]
97% 
[90-99%]
94% 
[86-98%]
PPV 71%
[36-92%]
86%  
[49-97%]
83% 
[44-97%]
58% 
[41-74%]
67% 
[30-90%]
43% 
[16-75%]
NPV 91%
[81-96%]
99%  
[92-100%]
100%
[95-100%]
74% 
[60-85%]
100% 
[95-100%]
99% 
[92-100%]
a Estimates are given as percentages with 95% confidence intervals in brackets
b  MDR-TB, multidrug-resistant tuberculosis; PPV, positive predictive value; NPV, negative predictive value; XDR-TB, 
extensively-resistant tuberculosis
Clinical relevance of different screening strategies
Different real-life screening strategies were undertaken during the study period. These are 
shown in Table 5. Screening on request (strategy II) instead of a general screening (strategy 
I) did not change diagnostic accuracy, but would lower the number of isolates screened. We 
calculated whether screening in high-risk groups only would improve diagnostic accuracy 
(Table 5). Compared with strategy I, screening in high-risk groups (strategy III) did not 
change diagnostic accuracy of the MDRTBplus assay to detect MDR-TB. Implementing this 
algorithm would have missed one patient with an rifampicin resistant, isoniazid susceptible 
M. tuberculosis isolate but no MDR-TB case. 
Table 5 
Effect of different screening strategies on the diagnostic accuracy of the MTBDRplus assay to detect 
MDR-TB
strategy I strategy II strategy IIIa
Screening strategy Screening every  
patient
On-demand of  
referring clinician
Screening risk  
groups
year 2009-2010 2011-2012 2009-2010
Total number 1569 918 1293
MDR-TB prevalence 32 (2%) 28 (3%) 32 (2%)
Sensitivity 100% [89-100%] 100% [88-100%] 100% [89-100%]
Specificity 99% [99-100%] 99% [98-99%] 99% [98-99%]
Positive predictive value 71% [57-82%] 72% [56-83%] 73% [58-84%]
Negative predictive value 100% [100-100%] 100% [100-100%] 100% [100-100%]
a  This represents a hypothetical group from the 2009-2010 sample. Risk groups were: foreign-born, age < 45 years 
and prior TB-treatment
DIsCussIon
In the present study we determined the diagnostic accuracy of the GenoType® MTBDRplus 
and MTBDRsl assay to detect phenotypic drug resistance to antituberculosis drugs in the 
context of routine diagnostics in a high-resource, low-level drug resistance setting. We found 
that molecular DST had excellent accuracy for detecting phenotypic resistance to isoniazid, 
good accuracy for detecting resistance to rifampicin, amikacin and moxifloxacin, but modest 
to poor accuracy for detecting resistance to capreomycin and ethambutol. 
The present study complements previous studies on the performance of the MTBDRplus assay in 
low-burden TB countries. Previous meta-analyses have raised questions on the applicability of the 
MTBDRplus assay to detect MDR-TB in such low-level drug resistant settings, suggesting that positive 
predictive value might be as low as 59%.2 In the present study the positive predictive value was 71%, 
probably because we used indirect DST. A recent laboratory study in the UK, another high-resource 
low-level drug resistance setting, showed similar accuracy for rifampicin resistance but found fewer 
false-positive results.7 This difference might be explained by their use of the LJ medium instead of 
the MGIT 960 system as the reference standard. We have previously reported that many of these 
presumably false-positive mutations occurred at positions of the rpoB gene that are associated with 
discordant, susceptible results in the MGIT 960 system and these mutations may in fact lead to low-
level rifampicin resistance and treatment failure.13,16 
Molecular drug susceptibility testing for first-line and | ChapTer seVenChapTer seVen |  Molecular drug susceptibility testing for first-line and  
second-line antituberculosis drugs in the Netherlands second-line antituberculosis drugs in the Netherlands
98 99
Our results are in line with a recent meta-analysis by Feng and co-workers on the performance 
of the MTBDRsl assay for detecting phenotypic drug resistance.3 In their meta-analysis, they 
found a similar performance of the MTBDRsl assay to detect fluoroquinolone and amikacin 
resistance but sensitivity to capreomycin was higher compared to the present study. The 
relative small number of isolates with rss mutation in our sample might have caused this 
difference, as well as the higher proportion of A1401G mutations we found in the rrs gene. 
These mutations are associated with high-level amikacin resistance, but low-level resistance 
to capreomycin.17 
Many of the previous studies on the accuracy of the MTBDRsl assay do not well reflect low-
level drug resistance settings.10,18-20 In our previously published article on the accuracy of 
the MTBDRsl assay for instance,10 prevalence of amikacin and moxifloxacin resistance was 
28% and 24% respectively, while corresponding proportions for MDR-TB isolates in the 
Netherlands are 10% and 7% (Table 1). Given the low prevalence and the concomitant high 
negative predictive value of both aminoglycosides and fluoroquinolones found in the present 
study, our results suggests that the MTBDRsl assay should best be used to rule out phenotypic 
resistance to these drugs in low-level drug resistance countries such as the Netherlands.
Our results also confirm the poor performance of embB mutations for detecting ethambutol 
resistance. A recent meta-analysis by Cheng and co-workers showed a similar sensitivity 
and specificity for detecting ethambutol resistance of the MTBDRsl assay (55% and 71%).21 
This poor performance of the MTBDRsl assay is probably caused by the inherent difficulties 
in phenotypic DST for ethambutol and by the fact that only mutations at position 306 are 
screened with this assay.21 Given the poor performance of the MTBDRsl assay, it seems that 
this assay can neither be used for detecting nor for ruling our ethambutol resistance accurately 
in settings such as the Netherlands and clinicians should await phenotypic DST before 
deciding to change treatment regimens.
The present study provides suggestions for applying molecular DST in the Netherlands. Given 
the low prevalence of MDR-TB (1%) a case-detection strategy applying the MTBDRplus assay (or 
any equivalent) for every suspected TB case might lead to unwanted overtreatment, might draw 
unnecessary financial burden on public health programs and might not be cost-effective.4,22 An 
alternative strategy would be to improve accuracy by screening in high-risk groups only. We showed 
that the common risk factors such as previous treatment, age and foreign-born were insufficient to 
increase predictive value in the Netherlands and might lead to missing drug- resistant TB cases with 
potential MDR-TB transmission, even when using indirect DST (reflex testing). This would tip the 
scale in favour for screening every proven M. tuberculosis complex isolate in low-burden countries.
We would propose to include a MTBDRsl assay and a pncA gene analysis in every isolate 
with an rpoB mutation to further guide treatment initiation in these patients. The chances 
of additional resistance are negligible if an isolate would have a wild type gyrA, rss and pncA 
gene. We would initiate first-line antituberculosis treatment together with moxifloxacin 
and amikacin in these patients. A concomitant katG or inhA mutation would strengthen 
the diagnosis of MDR-TB and favour initiating MDR-TB treatment without rifampicin and 
isoniazid. A pncA mutation would suggest a pyrazinamide-resistant MDR M. tuberculosis,13 in 
which case we would propose to initiate MDR-TB treatment with second-line antituberculosis 
drugs only. A gyrA mutation would suggest an XDR M. tuberculosis in two-third of cases 
(Table 4), in which case we would await further phenotypic DST before initiating treatment.
In conclusion, the present study has shown that the MTBDRplus and MTBDRsl assays are 
tools for rapid drug susceptibility testing to first-line and second-line antituberculosis drugs in 
the Netherlands. They may aid in decision making in tuberculosis treatment in low-level drug 
resistance settings and should preferably be used to exclude resistance.
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Antimycobacterial activity of phenothiazines 
and SILA 421
adapted from:
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J., Christensen J. B., Viveiros M., Riedl Z., Amaral L., van Soolingen D. Activity of the efflux 
pump inhibitor SILA 421 against drug-resistant tuberculosis.
International Journal of Antimicrobial Agents 2013; 41: 488-489.
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absTraCT
Background: Phenothiazines and SILA 421 are promising antituberculosis drugs targeting 
efflux pumps of both the mycobacteria and the macrophages that engulf them. They have 
proven activity against Mycobacterium tuberculosis in vitro as well as in vivo. 
Design: In this study, we compared the in vitro activity of multiple phenothiazines and SILA 
421 against 21 M. tuberculosis strains with different drug susceptibility patterns, using the 
Middlebrook 7H10 agar dilution method. Because the S-enantiomer of thioridazine might 
induce less neurotropism, we tested the activity of both enantiomers separately. 
Results: Chlorpromazine, thioridazine and SILA 421 showed equal activity with an MIC50 
and MIC90 of 4 and 16 mg/l, respectively. The S-enantiomer and R-enantiomer of thioridazine 
proved equally active in vitro. Desipramine and promazine showed little antimycobacterial 
activity. 
Conclusions: This study confirms that phenothiazines and SILA 421 hold promise as 
antituberculosis drugs. The unabated activity of the S-enantiomer of thioridazine may enlarge 
the applicability of phenothiazines in tuberculosis treatment.
InTroDuCTIon
The worldwide spread of multidrug-resistant (MDR) and extensively drug resistant (XDR) 
tuberculosis (TB) has been a major incentive in the search for new classes of antituberculosis 
drugs. Efflux pump inhibitors are one of those novel antituberculosis drug classes.1 The 
antimycobacterial effect of efflux pump inhibitors is postulated to be threefold. First, 
targeting mycobacterial efflux pumps decreases survival of M. tuberculosis.2 Second, efflux 
pump inhibitors increase susceptibility to other antituberculosis drugs by inhibiting efflux 
mechanisms partially responsible for antimycobacterial drug resistance.3 Third, efflux pumps 
can inhibit calcium efflux pumps of the phagolysosomes of macrophages thereby enhancing 
the killing activity of the pulmonary macrophages containing the entrapped M. tuberculosis 
bacteria.4
Among the efflux pump inhibitors capable of killing M. tuberculosis are organosilicon 
compounds, of which SILA 421 has been shown to have potential as an antituberculosis drug.5 
It shares the three pathways of antimycobacterial killing with other efflux pump inhibitors: it 
revealed direct in vitro activity against M. tuberculosis,5 it has been shown to modify resistance 
by inhibiting mdr-1 efflux pumps6 and has shown to enhance killing of M. tuberculosis by 
macrophages.5 
Another class of efflux pump inhibitors enhancing the killing of M. tuberculosis are the 
neuroleptic phenothiazines and the phenothiazine analogues thioxanthenes.7-9 The MICs of 
phenothiazines against M. tuberculosis vary from 4 to 16 mg/l depending on the medium 
used.10 Thioridazine, one of the phenothiazines, revealed the highest in vitro activity.7,10 
Subsequent animal studies have shown that thioridazine, as a sole drug and in combination 
with other antituberculosis drugs, was able to reduce bacterial loads in mice infected with 
drug-susceptible or MDR-TB.11,12 Moreover, thioridazine has been used on a compassionate 
basis in MDR and XDR-TB patients.1,13 
The use of thioridazine has been limited by its neurological and cardiac side-effects.1,13 
The neurological side-effects are caused by blocking of the dopamine (D2) receptor by 
thioridazine.14 It has hypothesized that the stereoselective S-enantiomer of thioridazine might 
induces less neurological side effects, putatively favouring the S-enantiomer to be used as 
antituberculosis drug instead of its racemate.14,15 
SILA 421 and the stereoselective S-enantiomer of thioridazine are promising additions to 
the spectrum of antituberculosis efflux pump inhibitors. However, these have only been 
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tested against a small number of M. tuberculosis isolates.5,15 We therefore assessed the 
antimycobacterial activity of SILA 421 against an extended set of M. tuberculosis strains with 
varying drug susceptibility profiles. Second, we compared the antimycobacterial activity of 
SILA 421 with that of thioridazine, its enantiomers and other phenothiazines.
MaTerIals anD MeThoDs
bacterial strains
We selected 21 clinical M. tuberculosis isolates to serve as a panel for the evaluation of the 
in vitro antimycobacterial activity of SILA 421, the phenothiazines and both thioridazine 
enantiomers: Five pansusceptible, 11 monoresistant (6 isoniazid monoresistant, 4 rifampin 
monoresistant and 1 streptomycin monoresistant) and 5 multidrug-resistant clinical isolates 
were selected. These originated from the collection of the National Tuberculosis Reference 
Laboratory (Bilthoven, the Netherlands). Mycobacterium tuberculosis strains had been 
identified using the Genotype MTBC assay (Hain Lifescience, Nehren, Germany) and 
susceptibility testing to antituberculosis drugs had been performed using the Mycobacteria 
Growth Inhibitor Tube 960 system (MGIT 960) according to the manufacturer’s instruction 
(Becton Dickinson, NJ, USA). 
antimicrobial agents
All drugs were received as chemically pure powder. Chlorpromazine, desipramine, promazine 
and thioridazine (TZsigma) were obtained from Sigma-Aldrich (Zwijndrecht, the Netherlands). 
The two thioridazine enantiomers were prepared by Dr. J.B. Christensen (Dept. Chemistry, 
Copenhagen, Denmark) according to the procedure described by Bourquin previously.16 The 
racemic form was prepared by mixing equal 1:1 amounts of the two enantiomers. SILA 421 
was provided by Dr. G. Hajos (Institute for Biomolecular Chemistry, Budapest, Hungary). All 
drugs were dissolved in distilled water to a stock solution of 10 g/l after which dilutions of 
anti-tuberculosis drugs were prepared, ranging from 1 mg/l to 16 mg/l.
Drug susceptibility testing
The Minimal Inhibitory Concentration (MIC) was determined using a Middlebrook 7H10 
agar dilution method as described previously.17 In short, isolates were extracted from a -70 
°C freezer collection and sub-cultured on Ogawa medium. 25-Well plates containing 23 wells 
with different concentrations of the antimicrobial drugs (1, 2, 4, 8, 16 mg/l), as well as one 
control well with drug free medium were inoculated with 10 µL of M. tuberculosis suspension 
aiming at 2 x 103 to 10 x 103 CFU. Another control well was inoculated with a 1:100-diluted 
suspension. The MIC was defined as the lowest concentration of an antituberculosis drug that 
inhibits more than 99% of the growth of the mycobacterial culture and was determined by 
comparing the growth of the drug enriched well with the 1:100-diluted control well.
resulTs 
The MICs could be determined after a median of 14 days (range 14–18 days). Table 1 gives 
the MIC50 (MIC at which 50% of the isolates are inhibited) and MIC90 (MIC at which 90% 
of the isolates are inhibited) values of SILA 421 and the various phenothiazines. The MIC50 
of SILA 421 was similar to the MIC50 of thioridazine and chlorpromazine, namely 4 mg/l. 
SILA 421 showed lowest MIC90. In contrast, desipramine and promazine revealed limited 
antimycobacterial activity with MIC50 and MIC90 > 16 mg/l. Table 1 also depicts the effect of 
chirality of thioridazine on the activity against M. tuberculosis. The antimycobacterial activity 
of the S-enantiomer did not differ from the R-enantiomer. The MIC50 of these enantiomers 
amounted to 8 mg/l and the MIC90 to 16 mg/l. 
Table 1 
The MIC50 and MIC90 of SILA 421 and the various phenothiazinesa
Efflux pump inhibitor MIC50 (mg/l) MIC90 (mg/l) range (mg/l)
SILA 421 4 8 2 - 16
Thioridazine 4 16 2 - 16
Thioridazine, S-enantiomer 8 16 4 - 16
Thioridazine, R-enantiomer 8 16 4 - 16
Chlorpromazine 4 16 <1 - 16
Desipramineb >16 >16 16 - >16
Promazineb >16 >16 16 - >16
a MIC50, MIC at which ≥ 50% of isolates are inhibited. MIC90, MIC at which ≥ 90% of isolates are inhibited.
b MIC distribution was based on 20 instead of 21 isolates.
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DIsCussIon
In the present study, we showed that Sila 421 has antimycobacterial activity similar to that 
of thioridazine in vitro, when tested against a wide variety of M. tuberculosis strains. Second, 
we confirmed the antimycobacterial activitiy of the phenothiazines and showed that the 
thioridazine S-enantiomer proved as effective as its racemate.
In a previous study, SILA 421 has been proposed to be more potent that thioridazine.5 
However, only two M. tuberculosis isolates were tested. The present study confirms that 
SILA 421 may be a promising antituberculosis drug with activity against a wide variety of 
M. tuberculosis strains comparable to that of thioridazine. Further studies are warranted to 
investigate the potency of SILA 421 as an antituberculosis drug in animals and in humans. 
Besides its antimycobacterial activity, SILA 421 might also have another appealing feature. 
Like all efflux pump inhibitors, SILA 421 will inhibit the activity of efflux pumps of MDR 
mycobacteria, presumptively rendering mycobacteria more susceptible to the antituberculosis 
drugs to which it was initially resistant as a consequence of their extrusion from the cell.1 
Thus, these drug resistance modifiers might be of interest not only for their immediate 
antimycobacterial activity but also as an adjunctive agent to be added to new or existing 
antituberculosis regimens. 
Our study confirms that phenothiazines and their derivatives are active against M. 
tuberculosis. Other studies have found similar results for promazine,7 thioxanthenes,8 
thioridazine,18 and the thioridazine enantiomers.15 By providing a MIC distribution of these 
drugs in a wider variety of M. tuberculosis strains and by showing that the MIC for all drugs 
was relatively constant with a MIC50 of 4 mg/l for most drugs, the present study extends the 
knowledge on the antimycobacterial activity of this class of drugs.
Of additional interest is our finding that the S-enantiomer of thioridazine is as effective as 
thioridazine itself against M. tuberculosis. It is thought this S-enantiomer might induce less 
neurological side effects owing to a lower affinity to the D2 dopamine receptor,14 putatively 
favoring the S-enantiomer over the racemate as an antituberculosis drug. However, it is 
unknown if the D2 dopamine receptor is the only target for neurological side-effects of 
thioridazine and it is unclear whether the pharmacokinetic and pharmacodynamic properties 
of the thioridazine enantiomers are equal. Notwithstanding these limitations, our findings 
raise hope that structural optimization of thioridazine-derivatives is possible without losing 
antimycobacterial activity.14 
In conclusion, the present study provides confirmatory and incremental evidence of 
the antimycobacterial activity of SILA 421 and the phenothiazines, such as thioridazine. 
Therapeutic opportunities lay in the structural optimization of these drugs as well as in their 
drug resistance modifying effect. Future studies should bring SILA 421 and the phenothiazines 
further up the drug development pipeline.
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absTraCT
Repositioning approved antimicrobial drugs is gaining attention as means to speed up anti-
tuberculosis drug development. We determined the MIC50 of 6 licensed antimicrobial agents 
in 13 drug-resistant Mycobacterium tuberculosis strains using the MGIT 960 system. Fusidic 
acid (8 mg/l), mefloquine (16 mg/l), nitrofurantoin (32 mg/l), co-trimoxazole (2:38 mg/l), 
amoxicillin with clavulanic acid (8/8 mg/l), and meropenem with clavulanic acid (2/2.5 mg/l) 
all showed antimycobacterial activity suggesting that they, or another class representative, 
could be repositioned as antituberculosis drugs. This calls for a reappraisal of other approved 
antimicrobial agents as potential anti-TB drugs. 
InTroDuCTIon
Despite global control efforts, multidrug-resistant (MDR) and extensively drug-resistant 
(XDR) tuberculosis (TB) notifications are still increasing.1 One of the barriers to the successful 
control of this disease is the long and cumbersome treatment using poorly tolerated second-
line antituberculosis (anti-TB) drugs.2 The growing problem of treating MDR-TB and XDR-TB 
has put pressure on the international community to speed up the development of new anti-TB 
drugs.1 
In view of this, the concept of repurposing existing drugs for the treatment of drug-resistant 
TB is gaining attention.3 It is the new use for existing approved drugs as anti-TB drugs.3 
Examples of such repurposed drugs currently in use for treating MDR-TB and XDR-TB are 
linezolid and meropenem with clavulanic acid.1,4 Linezolid was originally introduced for 
treating nosocomial pneumonia and skin infections, but also proved to be active against M. 
tuberculosis in 1991.5 Recent meta-analyses have shown that the use of linezolid-containing 
treatment regimens is associated with favorable outcomes.6,7 The first report of the 
antimycobacterial activity of meropenem with clavulanic acid dates to 2009.8 Since then case-
control studies have reported that regimens including meropenem with clavulanic acid are 
associated with a better sputum-smear conversion at 3 months.9 As a result, the most recent 
TBNET consensus statement has suggested that both linezolid and meropenem/clavulanic 
acid may be used for the treatment of MDR- and XDR-TB.4 
Besides these two drugs there are other antimicrobial agents on the market with some 
effectiveness against TB. These are amoxicillin with clavulanic acid, thioridazine, 
metronidazole, doxycycline and co-trimoxazole.10 All these drugs have proven in vitro activity 
against M. tuberculosis and some have been studied in (MDR)-TB patients, albeit with varying 
success.11,12 There has also been some anecdotal evidence of the antimycobacterial activity of 
other antimicrobial agents, such as fusidic acid,13 nitrofurantoin14 and mefloquine.15 
The antimycobacterial activity of these existing antimicrobial agents are hints suggesting 
that we are currently not using all potentially available drug classes. The relevance of the 
antimycobacterial activity of these agents may be underappreciated owing to limited in vitro 
data on clinical isolates; proper MIC distributions have only been published for thioridazine 
and co-trimoxazole.16-18 The goal of the present study was to extend the knowledge of the 
antimycobacterial activity of these agents by providing a MIC distribution from a panel of 
various clinical M. tuberculosis isolates. 
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MaTerIals anD MeThoDs
sample collection
We selected 12 clinical M. tuberculosis isolates and the H37Rv reference strain to serve as a 
panel for the in vitro activity against M. tuberculosis. The clinical isolates originated from the 
collection of the National Tuberculosis Reference Laboratory (Bilthoven, the Netherlands) and 
some of these isolates have been used previously as a panel for testing susceptibility for other 
(novel) antituberculosis drugs.16,18
Mycobacterium tuberculosis strains had been identified using the Genotype MTBC assay 
(Hain Lifescience, Nehren, Germany). The 13 strains had a known susceptibility pattern to 
first- and second-line drugs, as determined using the Mycobacteria Growth Indicator Tube 
960 (MGIT 960; Becton Dickinson, Erebodegem, Belgium) and Middlebrook 7H10 agar 
dilution method.19,20 Multidrug-resistant (MDR) tuberculosis was defined as isolates that were 
resistant to at least rifampicin and isoniazid. Extensively resistant (XDR) tuberculosis was 
defined as isolates that were resistant to rifampicin, isoniazid, a second-line injectables and a 
fluoroquinolone.
antimicrobial agents
The six antimicrobials agents were all acquired through Sigma Aldrich (Zwijndrecht, the 
Netherlands). The drug concentrations that were tested are depicted in Table 1. These drug 
concentrations were chosen on the basis of previous publications using liquid media.8,14,15,21-23 
We used trimethoprim and sulfamethoxazole in a 1:19 ratio.22 Amoxicillin was tested using a 
fixed clavulanic acid concentration of 8 mg/l.21 We tested meropenem with and without a fixed 
clavulanic acid concentration of 2.5 mg/l.8. Based on previous observations (D. van Soolingen, 
personal communication) meropenem without clavulanic acid was tested in concentrations 
from 4 to 64 mg/l, while meropenem with clavulanic acid was tested in concentrations from 
0.25 to 8 mg/l.
Table 1 
Drug concentrations used for drug susceptibility testinga
Drug Concentrations evaluated (in mg/l)
Amoxicillin with clavulanic acidb 2, 4, 8, 16, 32
Trimethoprim-sulfamethoxazole 0.5:9.5, 1:19, 2:38, 4:76, 8:152
Fusidic acid 4, 8, 16, 32, 64
Mefloquine 2, 4, 8, 16, 32
Meropenem, with and without clavulanic acidc 0.25, 0.5, 1, 2, 4, 8, 16, 32
Nitrofurantoin 4, 8, 16, 32, 64
a The MGIT 960 system was used for drug susceptibility testing. 
b Amoxicillin was tested with a fixed clavulanic acid concentration of 8 mg/l.
c Meropenem was tested with and without a fixed clavulanic acid concentration of 2.5 mg/l.
Drug susceptibility testing
The minimum inhibitory concentrations (MIC) were determined using the MGIT 960 system. 
To prepare inocula, isolates were extracted from a -70 ºC freezer collection an sub-cultured 
in MGIT medium. One or two days after the MGIT tube turned positive, the culture was 
mixed by vortexing and allowed to settle for 5-10 minutes as instructed by the manufacturer 
(Becton Dickinson, Erebodegem, Belgium). We then added 0.5 ml of M. tuberculosis broth 
supernatant, 0.8 ml of Bactec MGIT growth supplement (oleic acid, albumin, dextrose, 
catalase; OADC) and 0.1 ml of appropriate drug solution to a new MGIT tube. A growth 
control tube was simultaneously prepared with a 1:100-diluted 0.5 ml inoculum. All tubes 
were incubated at 37 ºC and read when the growth control tube had reached a growth value 
(GU) of 400.24 The minimum inhibitory concentration (MIC) was defined as the lowest 
concentration in which the GU of the drug-containing culture tube was <100.24 Results 
were summarized for each drug using the MIC50 and MIC90. Some of these results have been 
published previously as an abstract.
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resulTs
The susceptibility pattern and the individual MICs of the 12 clinical isolates and the H37Rv 
reference strain is shown in Table 2. Three isolates were fully susceptible, one isolate was 
ethambutol monoresistant, 2 isolates were isoniazid and ethambutol resistant, five were MDR 
M. tuberculosis isolates and three XDR M. tuberculosis isolates. 
Table 2 
The MICs (in mg/l) of six antimicrobial agents in 13 susceptible and drug-resistant M. tuberculosis 
strains
strain no. susceptibilitya antimicrobial agentb,c
aMC MeM MeC sXT fus Mef nIT
H37Rv Pansusceptible 16 < 2 0.5 < 0.5:9.5 < 4 8 32
NLA009600108 Pansusceptible < 2 8 1 1:19 8 16 32
NLA000900234 Pansusceptible 16 16 1 4:76 < 4 4 8
NLA009800610 E resistant < 2 8 2 < 0.5:9.5 < 4 16 > 64
NLA000401745 H & S resistant
 16 > 32 > 4 < 0.5:9.5 8 16 64
NLA000201682 MDR 4 32 2 1:19 < 4 8 64
NLA000301128 MDR 8 16 1 < 0.5:9.5 4 8 32
NLA000401230 MDR 4 8 1 2:38 8 16 32
NLA000801695 MDR < 2 4 0.5 4:76 16 16 32
NLA000801810 MDR < 2 16 2 2:38 < 4 8 32
NLA000900268 XDR > 32 > 32 > 4 2:38 32 16 64
NLA000901542 XDR 8 16 2 4:76 32 16 32
NLA000901844 XDR 8 32 2 2:38 8 8 32
a E, ethambutol; H, isoniazid; MDR, multidrug-resistant; S, streptomycin; XDR, extensively drug-resistant.
b  AMC, amoxicillin with clavulanate; MEM, meropenem; MEC, meropenem with clavulanate; SXT, trimethoprim-
sulfamethoxazole; FUS, fusidic acid; MEF, mefloquine; NIT, nitrofurantoin.
c  Amoxicillin (AMC) and meropenem (MEC) were tested with a fixed clavulanate concentration of 8 mg/l and 2.5 mg/l, 
respectively.
We observed in vitro antimycobacterial activity against both susceptible and drug-resistant 
M. tuberculosis for all six antimicrobial agents (Table 2). The MIC50 (the MIC at which 50% 
of the isolates are inhibited) and MIC90 (the MIC at which 90% of the isolates are inhibited) 
for amoxicillin with clavulanic acid were 8 mg/l and 16 mg/l respectively. We first tested 
meropenem without adding clavulanic acid because meropenem is a poor substrate for the 
BlaC β-lactamase of M. tuberculosis.8 We noted a MIC50 of 16 mg/l and a MIC90 of > 32 mg/l. 
Addition of 2.5 mg/l clavulanic acid lowered the MIC50 to 2 mg/l. Clavulanic acid itself had no 
antimycobacterial activity (data not shown).
Besides β-lactam antibiotics, we also tested susceptibility to co-trimoxazole. We found 
that the MIC50 was 2:38 mg/l and the MIC90 was 4:76 mg/l. We additionally tested the 
antimycobacterial activity of fusidic acid, mefloquine and nitrofurantoin (Table 2). The MIC50 
for fusidic acid was 8 mg/l and the MIC90 was 32 mg/l. For mefloquine, the MIC50 was 16 mg/l 
and the MIC90 was and 16 mg/l. The MIC50 of nitrofurantoin amounted to 32 mg/l and the 
MIC90 to 64 mg/l.
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DIsCussIon
The present study provides confirmatory and incremental evidence that amoxicillin with 
clavulanic acid, meropenem with clavulanic acid and co-trimoxazole could be repurposed 
as antituberculosis drugs against MDR/XDR-TB. Secondly, fusidic acid, mefloquine and 
nitrofurantoin also showed antimycobacterial activity suggesting that class representatives 
could be used as novel antituberculosis drugs. 
We measured MICs to meropenem/clavulanic acid using the MGIT960 system and found 
that MICs were higher than those reported by Hugonnet and colleagues.8 Using a Middlebrook 
7H9 broth medium, they reported an MIC50 of 0.625 mg/l and an MIC90 of 1.25 mg/l, whereas 
in the present study MIC50 and MIC90 were 2 mg/l and > 4 mg/l. This discrepancy may be 
partly explained by the fact that Hugonnet and colleagues used a microdilution assay and 
tested additional intermediate concentrations for more exact MIC titration. Also, meropenem 
may lose activity with time in the 7H9 medium,25 thereby complicating accurate interpretation 
of the MICs. Nonetheless, our results suggest that the activity of meropenem with clavulanic 
acid might be lower than previously anticipated. 
The present study confirms that co-trimoxazole has potential as an antituberculosis drug. It is 
an attractive alternative because of its pharmacokinetic profile, its low costs and good tolerance 
in TB patients.10,26 Its mechanism of acting is through inhibition of the folic acid metabolism.10 
The present MIC distribution in MDR/XDR M. tuberculosis isolates might help future 
pharmacokinetic and –dynamic studies in setting the optimal dose.26
The other antimicrobial agents also revealed in vitro activity against M. tuberculosis. The 
MICs found for fusidic acid were lower than those in previous studies 13,23, while the MICs of 
mefloquine and nitrofurantoin were similar to those found previously.14,15 These drugs should 
be viewed as examplars of their respective drug classes, providing clues for drug engineering of 
novel antituberculosis drugs (Table 3).27 Fusidic acid, for instance, binds to elongation factor G 
thereby preventing its release from the ribosome.28 Nitrofurantoin, in turn, is converted into 
a reactive intermediate via type 1 oxygen insensitive nitroreductases,29 rendering nitrofurans 
attractive drugs against dormant mycobacteria. Mefloquine inhibits F0F1 H+-ATPase echoing 
the mode of action of bedaquiline.30
The present study provided a range of MICs for the six agents in 12 clinical drug-resistant 
M. tuberculosis isolates. Future studies in larger strain collections should therefore aim to 
correlate these MICs to PK/PD parameters. If these yield encouraging results, the next step 
would be to test these drugs in preclinical models, e.g. hollow fiber models and mouse models, 
before progressing to clinical trials. Only the latter will ascertain the true potential of these 
drugs as antituberculosis drugs. 
In conclusion, our findings suggest that existing drugs indeed may have new uses in the 
treatment of drug-resistant TB. All six approved antimicrobial agents tested in the present 
study showed in vitro antimycobacterial activity suggesting that they, or another class 
representative, could be repositioned as antituberculosis drugs. This calls for a reappraisal of 
other approved antimicrobial agents as potential antituberculosis drugs.
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Introduction 
The emergence of multidrug-resistant tuberculosis (MDR-TB) threatens global tuberculosis 
control. This has sparked a renewed interest in developing new antituberculosis drugs and 
regimens. To be safe and effective, the introduction of these new treatment regimens should 
be aligned with drug susceptibility testing (DST). Drug susceptibility testing is essential 
because it can identify patients who will benefit from treatment and because it can be used to 
monitor patterns of emerging drug resistance in the community. Which DST strategy is best 
depends on the prevailing drug resistance level, the selection of patient population eligible 
for testing, and the health-care system implementing the algorithm. This should be preceded 
by a thorough understanding of the accuracy and performance of the different diagnostic 
strategies, in real-life settings and under different epidemiological situations. This has been 
the main topic of this thesis. 
Methods for drug susceptibility testing 
We provided an introduction to the different methods for DST in TB in chapter 2. DST 
has classically been performed on solid media, such as the Löwenstein-Jensen medium. 
Semi-automated non-radiometric liquid culture systems, such as the Mycobacteria Growth 
Indicator Tube (MGIT) 960 system, have reduced the turn-around-time from months to 
weeks and will become the new gold standard in phenotypic DST. Unfortunately, DST in 
liquid media is still not fast enough for rapid DST. To this end, a molecular approach should 
be undertaken. This consists of detecting mutations in the M. tuberculosis genome that are 
associated with resistance to specific antituberculosis drugs. Examples of such resistance-
determining mutations are mutations in the rpoB gene associated with rifampicin resistance 
and mutations in the pncA gene encoding for the enzyme pyrazinamidase, which is essential 
for the activity of pyrazinamide. 
Detecting pyrazinamide resistance 
Pyrazinamide is an important first-line drug in the treatment of tuberculosis. The diagnosis of 
pyrazinamide resistance is challenging owing to a high proportion of false-resistance results 
in phenotypic DST. In chapter 3, we describe an algorithm for diagnosing pyrazinamide 
resistance that combines mutation analysis with culture-based methods. We hypothesized 
that nonsynonymous pncA mutations would be able to differentiate between true-resistant 
and false-resistant phenotypic (MGIT 960) susceptibility test results. To answer this 
question, we analysed 1,650 M. tuberculosis isolates sent for resistance testing to the Dutch 
National Tuberculosis Reference Laboratory from 2008 to 2009. We observed pyrazinamide 
resistance in 69 out of 1,650 samples after a first MGIT 960 analysis. However, 47 of the 69 
samples proved susceptible in a second MGIT test indicating a false-positive rate of 68% in 
the first MGIT 960 test. Sensitivity of nonsynonymous pncA mutations for detecting true 
pyrazinamide-resistant isolates was 73%, and specificity was 100%. The positive predictive 
value of a pncA mutation in detecting true pyrazinamide resistance was 100%, and the 
negative predictive value was 89%. We concluded that nonsynonymous pncA mutations were 
able to differentiate between true-resistant and false-resistant MGIT 960 results and proposed 
that all isolates labelled resistant after a first round of MGIT testing should undergo pncA gene 
sequence analysis. 
Pyrazinamide resistance is seen in an minority of M. tuberculosis strains carrying a wild type 
pncA gene and hence a normal functioning pyrazinamidase enzyme. It has recently been 
demonstrated that pyrazinamide might also inhibit the trans-translation by the ribosomal 
protein S1, which is required for efficient protein synthesis. Mutations in rpsA gene, which 
encodes for this protein, might therefore mediate pyrazinamide resistance in these pncA wild 
type strains. In chapter 4, we re-examined 5 pyrazinamide-resistant isolates with a wild-type 
pncA gene. Sequencing the rpsA gene revealed an A-to-G nucleotide change in codon 260 in 
one isolate only, leading to an amino acid change from valine to isoleucine. Incorporating rpsA 
gene sequencing in our proposed diagnostic algorithm (chapter 3) would modestly increase 
sensitivity from 73% to 77%.
While screening for pyrazinamide resistance can be carried out using the MGIT 960 system, 
molecular screening assays are preferred in high-burden countries. We describe such a 
molecular approach for identifying pyrazinamide-resistant MDR M. tuberculosis, applicable 
for high-burden settings in chapter 5. We hypothesized that pncA sequencing added to rpoB 
mutation analysis would accurately identify pyrazinamide-resistant MDR M. tuberculosis. 
To test our hypothesis, we sequenced the pncA gene in patient isolates with a known rpoB 
mutation and compared results with phenotypic drug susceptibility results to rifampicin, 
isoniazid and pyrazinamide. We included clinical M. tuberculosis isolates from 83 patients 
that were sent to our laboratory from 2007 to 2011. Phenotypic reference testing identified 
pyrazinamide-resistant MDR-TB in 31 isolates (48%). Sensitivity of pncA sequencing added to 
rpoB mutation analysis for detecting pyrazinamide-resistant MDR-TB was 97%, the specificity 
was 94%, the positive predictive value was 91%, and the negative predictive value was 98%. 
We concluded that pyrazinamide-resistant MDR-TB could be accurately detected using pncA 
sequencing added to rpoB mutation analysis and proposed to include pncA sequencing in 
every isolate with an rpoB mutation.
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Drug susceptibility testing to second-line drugs 
A variety of techniques are now available for DST to second-line antituberculosis drugs. In 
Chapter 6, we compared the Middlebrook 7H10 agar dilution method with the MGIT 960 
system and the GenoType MTBDRsl molecular assay. We selected 28 clinical multidrug- and 
extensively drug-resistant M. tuberculosis complex strains and M. tuberculosis H37Rv. We 
included amikacin, capreomycin, moxifloxacin, prothionamide, clofazimine, linezolid, and 
rifabutin in the phenotypic test panels. For amikacin, capreomycin, linezolid, and rifabutin, 
results obtained by all methods were fully concordant. All capreomycin- and amikacin-
resistant isolates carried rrs mutations. For prothionamide, concordance was noted only at 
the lowest and highest MICs. Applying a MGIT 960 breakpoint of 0.5 mg/l for moxifloxacin 
led to results concordant with those of both the agar dilution method and the genotypic 
method. Our study supports the following breakpoints for the MGIT 960 method: 1 mg/l for 
amikacin, linezolid, and clofazimine, 0.5 mg/l for moxifloxacin and rifabutin, and 2.5 mg/l 
for capreomycin. For prothionamide, a division into susceptible, intermediate, and resistant 
seems warranted. 
rapid molecular DsT in the netherlands 
Studies on the performance of molecular screening tests for drug resistance, such as the 
MTBDRplus and MTBDRsl assay, have mostly been performed in high-burden TB countries. 
There is a need to generate more evidence on diagnostic accuracy and health-program related 
outcomes of these tests in low-incidence, high-resource countries. The Netherlands is such 
a low-level drug resistance country. In chapter 7, we evaluated the diagnostic accuracy of 
the MTBDRplus and the MTBDRsl test in 2,649 and 74 clinical isolates from a national-wide 
screening program (2007-2012) in the Netherlands to detect resistance to first-line and second-
line antituberculosis drugs. The MTBDRplus assay had a sensitivity, specificity, positive and 
negative predictive value of 100%, 99%, 80% and 100% for detecting rifampicin resistance. 
Sensitivity, specificity, positive and negative predictive value of a katG mutation for detecting 
isoniazid resistance was 55%, 100%, 100% and 94%. Sensitivity, specificity, positive and 
negative predictive value of a inhA or katG mutation for detecting isoniazid resistance was 
88%, 100%, 100%, 98%. The MTBDRsl assay had a sensitivity, specificity, positive and negative 
predictive value of 100%, 99%, 83%, and 100% for detecting moxifloxacin resistance. The 
MTBDRsl assay had a sensitivity, specificity, positive and negative predictive value of 86%, 
99%, 86%, and 99% for detecting amikacin resistance. Sensitivity, specificity, positive and 
negative predictive value was 50%, 96%, 71% and 91% for detecting capreomycin resistance and 
62%, 71%, 58% and 74% for detecting ethambutol resistance. In conclusion, the MTBDRplus 
and MTBDRsl assay can be used as a tool for rapid susceptibility testing to first-line and 
second-line antituberculosis drugs in the Netherlands. The high negative predictive suggests 
that these tests should preferably be used to exclude resistance in low-level drug resistance 
settings, such as in the Netherlands.
repurposing existing drugs as antituberculosis agents 
To increase the arsenal of antituberculosis drugs, a successful approach has been to 
reposition existing drugs for tuberculosis treatment. Phenothiazines are examples of such 
repositioned antituberculosis drugs, targeting efflux pumps of both the mycobacteria and the 
macrophages that engulf them. In chapter 8, we compared the in vitro activity of multiple 
phenothiazines and SILA 421, an organicosilicon compound, against 21 M. tuberculosis 
strains with different drug susceptibility patterns, using the Middlebrook 7H10 agar dilution 
method. Because the S-enantiomer might induce less neurotoxicity than the R-enantiomer 
of thioridazine, we also tested both enantiomers separately. Chlorpromazine, thioridazine 
and Sila 421 showed equal activity with an MIC50 and MIC90 of 4 and 16 mg/l, respectively. 
The S-enantiomer and R-enantiomer of thioridazine proved equally active in vitro. In 
conclusion, this study provided incremental evidence of the antimycobacterial activity of 
SILA421 and the phenothiazines such as thioridazine. Therapeutic opportunities lie in the 
structural optimisation of these drugs as well as in their drug resistance-modifying effect. In 
chapter 9, we determined the MIC50 of 6 licensed antimicrobial agents in 12 drug-resistant M. 
tuberculosis strains and the H37Rv reference strain using the MGIT 960 system. Fusidic acid 
(8 mg/l), mefloquine (16 mg/l), nitrofurantoin (32 mg/l), trimethoprim-sulfamethoxazole 
(2:38 mg/l), amoxicillin/clavulanate (8/8mg/l), and meropenem/clavulanate (2/2.5 mg/l) 
all showed antimycobacterial activity suggesting that they, or another class representative, 
could be repositioned as antituberculosis drugs. This calls for a reappraisal of other approved 
antimicrobial agents as potential antituberculosis drugs.
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Introductie
De opkomst van multiresistente tuberculose vormt een bedreiging voor de wereldwijde 
controle van tuberculose. Dit heeft geleid tot een hernieuwde interesse in het ontwikkelen 
van nieuwe antituberculose medicijnen en behandelingsschema’s. Een veilige en effectieve 
introductie van dergelijke nieuwe medicijnen dient hand in hand te gaan met bepalen van 
resistentie tegen deze medicijnen. Resistentiebepalingen zijn essentieel omdat daarmee 
patiënten geïdentificeerd kunnen worden die baat zullen hebben bij de therapie en omdat 
hiermee resistentie op populatieniveau gevolgd kan worden. Welke algoritme het beste 
gebruikt kan worden hangt af van het resistentieniveau in de populatie, de patiëntenselectie, 
en het gezondheidszorgsysteem dat het algoritme moet borgen. Dit dient voorafgegaan 
te worden door het bepalen van de betrouwbaarheid en validiteit van de verschillende 
resistentiemethoden, onder praktijkomstandigheden en in verschillende epidemiologische 
settings. Dit is het belangrijkste onderwerp van dit proefschrift.
resistentiebepalingen
We hebben een overzicht gegeven van de verschillende resistentiebepalingen in hoofdstuk 
2. Resistentiebepalingen worden traditioneel verricht op vaste media, zoals een Löwenstein-
Jensen medium. Semiautomatische systemen op basis van vloeibare kweekmethoden, zoals 
het Mycobacteria Growth Indicator Tube (MGIT) 960 systeem, hebben de diagnostiek naar 
resistentie versneld van maanden naar weken. Deze systemen zullen op langere termijn de 
nieuwe gouden standaard worden voor fenotypische resistentiebepalingen. Helaas zijn deze 
vloeibare kweekmethoden nog niet snel genoeg. Hiervoor zullen moleculaire technieken 
noodzakelijk zijn. Deze bestaan uit het bepalen van specifieke mutaties in het genoom van M. 
tuberculosis die zijn geassocieerd met resistentie tegen bepaalde antituberculose medicijnen. 
Voorbeelden hiervan zijn mutaties in het rpoB gen, die zijn geassocieerd met resistentie 
tegen rifampicine, en mutaties in het pncA gen die coderen voor het enzym pyrazinamidase, 
essentieel voor de activiteit van pyrazinamide. 
het bepalen van pyrazinamideresistentie
Pyrazinamide is een belangrijk eerstelijns antituberculose medicijn. De diagnostiek naar 
pyrazinamide resistentie wordt bemoeilijkt door een hoog percentage fout-positieve 
uitslagen in de fenotypische resistentiemethoden. In hoofdstuk 3 beschrijven we een 
algoritme voor het bepalen van pyrazinamide resistentie op basis van een combinatie van 
moleculaire en fenotypische resistentiebepalingen. Onze hypothese was dat mutaties in het 
pncA gen konden voorspellen of een fenotypische kweekuitslag (MGIT 960) fout-positief 
of terecht-positief zou zijn. Dit hebben we onderzocht in 1.650 M. tuberculosis isolaten die 
tussen 2008 en 2009 naar het RIVM waren gestuurd voor resistentiebepalingen. In 69 van 
de 1.650 isolaten werd resistentie tegen pyrazinamide waargenomen na een eerste MGIT 
analyse. Echter 47 van de 69 bleken bij hernieuwde analyse toch pyrazinamide gevoelig te zijn 
(percentage fout-positieven 68%). De sensitiviteit van een pncA mutatie voor het bepalen van 
een terecht-positieve pyrazinamide resistente MGIT uitslag was 73% en de specificiteit was 
100%. De positief voorspellende waarde was 100% en de negatief voorspellende waarde was 
89%. We concluderen dat pncA mutaties resistentie tegen pyrazinamide nauwkeurig kunnen 
voorspellen en we adviseren om een pncA mutatieanalyse in te zetten in elk M. tuberculosis 
isolaat met een eerste pyrazinamideresistente MGIT uitslag.
Recent is een nieuw mechanisme voor pyrazinamideresistentie beschreven in M. tuberculosis 
isolaten met een wild type pncA gen en daardoor een functionerend pyrazinamidase 
enzym. Pyrazinamide zou de trans-translatie van het ribosomaal eiwit S1 belemmeren, 
wat noodzakelijk is voor de eiwitsynthese in M. tuberculosis. Mutaties in het rpsA gen, 
dat codeert voor het ribosomaal eiwit S1, zouden dan ook geassocieerd kunnen zijn met 
pyrazinamideresistentie in isolaten met een wild type pncA gen. Om dit te onderzoeken 
hebben we het rpsA gen gesequenst in vijf isolaten met een wild type pncA gen. Dit wordt 
beschreven in hoofdstuk 4. In slechts één van de vijf isolaten vonden we een nucleotide 
verandering van adenine naar guanine in codon 260 van het rpsA gen. Dit leidde tot een 
aminozuur verandering van valine naar isoleucine. Het toevoegen van rpsA mutatie analyse 
aan het diagnostisch algoritme uit hoofdstuk 3 leidde tot een marginale verbetering van de 
sensitiviteit van 73% naar 77%. 
Screening naar pyrazinamideresistentie gebeurt voornamelijk met het MGIT 960 systeem. 
Snellere, moleculaire screeningsmethoden worden bij voorkeur gebruikt in landen met 
een hoge prevalentie voor multiresistente tuberculose. In hoofdstuk 5 beschrijven 
een diagnostisch algoritme op basis van moleculaire resistentiebepalingen waarmee 
pyrazinamideresistente, multiresistente M. tuberculosis gediagnosticeerd kan worden. 
Onze hypothese was dat een mutatie in zowel het rpoB als het pncA gen voorspellend 
zou zijn voor een pyrazinamideresistente, multiresistente M. tuberculosis stam. Om dit te 
onderzoeken hebben we het pncA gen gesequenst van 83 M. tuberculosis isolaten met een 
rpoB mutatie. Deze waren tussen 2007 en 2011 ingestuurd naar het RIVM. De moleculaire 
uitslag werd vergeleken met fenotypische resistentiebepalingen tegen rifampicin, 
isoniazide en pyrazinamide. Pyrazinamideresistente, multiresistente tuberculose werd 
gezien in 31 isolaten (48%). De sensitiviteit van de moleculaire analyse voor de detectie van 
pyrazinamideresistente, multiresistente M. tuberculosis was 97%, de specificiteit was 94%, 
de positief voorspellende waarde was 91% en de negatief voorspellende waarde was 98%. 
Pyrazinamideresistente multiresistente M. tuberculosis kan dus nauwkeurig worden bepaald 
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met moleculaire technieken. We adviseren dan ook een pncA mutatieanalyse uit te voeren in 
elke isolaat met een rpoB mutatie.
resistentiebepalingen tegen tweedelijns antituberculose medicijnen
Er zijn verschillende technieken beschikbaar voor het bepalen van resistentie tegen 
tweedelijns antituberculose medicatie. We hebben in hoofdstuk 6 de Middlebrook 7H10 
agar dilutiemethode vergeleken met het MGIT 960 systeem en de GenoType MTBDRsl 
moleculaire methode. Hiervoor hebben we 28 klinische multi- en extensieve resistente M. 
tuberculosis complex stammen en de H37Rv referentie stam geselecteerd. Resistentie is 
getest tegen amikacine, capreomycine, moxifloxacine, prothionamide, clofazimine, linezolid 
en rifabutin. De resultaten van de verschillende technieken kwamen volledig overeen voor 
amikacine, capreomycine, linezolid en rifabutin. Alle capreomycine en amikacine resistente 
stammen hadden een mutatie in het rrs gen. Voor protionamideresistentie waren de resultaten 
voor de MGIT960 en de Middlebrook 7H10 alleen hetzelfde voor de hoogste en de laagste 
MIC waarden. Het toepassen van een 0.5 mg/l breekpunt concentratie voor moxifloxacine 
leidde tot een volledige overeenstemming met de Middlebrook agar dilutie methode en de 
moleculaire analyse van het gyrA gen. Op basis van deze studie worden de volgende breekpunt 
concentraties voorgesteld voor de MGIT 960 methode: 1 mg/l voor amikacine, linezolid en 
clofazimine, 0.5 mg/l voor moxifloxacine en rifabutin en 2.5 mg/l voor capreomycine. Voor 
prothionamide zou een onderscheid gemaakt moeten worden tussen gevoelig, intermediair en 
resistente stammen.
snelle moleculaire screening naar resistentie in nederland
De meeste studies naar de effectiviteit van moleculaire screeningsmethodes voor het bepalen 
van resistentie, zoals de MTBDRplus en de MTBDRsl test, zijn verricht in landen met een 
hoog prevalentie voor resistentie. Er zijn meer onderzoeken nodig voor het bepalen van de 
validiteit en klinische relevantie van deze methode in landen met een lage prevalentie voor 
resistentie. Nederland is een dergelijk laag prevalentie land. We hebben in hoofdstuk 7 de 
nauwkeurigheid van de MTBDRplus en de MTBDRsl test bepaald in 2.649 en 74 klinische 
isolaten die waren verkregen via een landelijk screeningsprogramma in Nederland (2007-12) 
naar het bepalen van resistentie tegen eerste- en tweedelijns antituberculose medicatie. De 
MTBDRplus test had een sensitiviteit, specificiteit, positief en negatief voorspellende waarde 
van 100%, 99%, 80% en 100% voor het detecteren van rifampicine resistentie. Sensitiviteit, 
specificiteit, positief en negatief voorspellende waarde van een inhA of een katG mutatie voor 
de detectie van isoniazide resistentie was 55%, 100%, 100% en 94%. De MTBDRsl test had een 
sensitiviteit, specificiteit, positief en negatief voorspellende waarde van 100%, 99%, 83%, en 
100% voor het detecteren van moxifloxacine resistentie. Sensitiviteit, specificiteit, positief 
en negatief voorspellende waarde van de MTBDRsl test voor de detectie van amikacine 
resistentie was 86%, 99%, 86%, en 99%. Dit was 50%, 96%, 71% en 91% voor de detectie van 
capreomycine resistentie. Sensitiviteit, specificiteit, positief en negatief voorspellende waarde 
voor het detecteren van ethambutol resistentie was 62%, 71%, 58% en 74%. Deze resultaten 
geven aan dat zowel de MTBDRplus als de MTBDRsl testen gebruikt kunnen worden voor 
de snelle detectie van resistentie tegen eerste- en tweedelijns antituberculose medicatie. De 
hoge negatief voorspellende waarde suggereert dat deze testen bij voorkeur ingezet moeten 
worden om resistentie uit te sluiten in landen met een lage prevalentie van resistentie, zoals in 
Nederland.
herpositioneren van bestaande medicatie als antituberculose 
medicijnen 
Het herpositioneren van bestaande medicatie voor het gebruik als antituberculose medicijn 
is een succesvolle manier om het arsenaal aan antituberculose medicatie te vergroten. 
Phenothiazines zijn een voorbeeld van dergelijke medicijnen, omdat zij efflux pompen 
kunnen blokkeren zowel in mycobacteriën als macrofagen. In hoofdstuk 8 hebben 
we de in vitro activiteit vergeleken van verschillende phenothiazines en van SILA421, 
een organicosilicon, tegen 21 M. tuberculosis stammen. Hiervoor gebruikten we een 
Middlebrook 7H10 agar dilutie methode. Daarnaast testten we activiteit van de verschillende 
enantiomeren van thioridazine, omdat het S-enantiomeer mogelijk minder neurotoxiciteit 
zou geven; een bekende bijwerking van thioridazine. Chloorpromazine, thioridazine en 
SILA 421 vertoonden vergelijkbare antimycobacteriële activiteit met een MIC50 van 4 mg/l 
en een MIC90 van 16 mg/l. De in vitro antimycobacteriële activiteit van het thioridazine 
S-enantiomeer was vergelijkbaar met die van het R-enantiomeer. Deze studie toont het 
potentieel aan van phenothiazines en SILA 421 als antituberculose medicijnen. Mogelijkheden 
tot optimalisatie van deze middelen liggen op het gebied van “drug engineering”. Deze 
efflux pomp remmers zouden ook ingezet kunnen worden om de gevoeligheid voor andere 
antituberculose medicatie te verhogen. Naast phenothiazines tonen andere medicatieklassen 
ook antimycobacteriële activiteit. In hoofdstuk 9, hebben we de antimycobacteriële activiteit 
onderzocht van zes geregistreerde antimicrobiële medicijnen. Hiervoor werden 12 resistente 
M. tuberculosis stammen en de H37Rv referentiestam gebruikt. Alle middelen toonden enige 
antimycobacteriële activiteit: de MIC50 van fusidinezuur was 8 mg/l, van nitrofurantoine 
32 mg/l, van co-trimoxazol 2:38 mg/l, van mefloquine 16 mg/l, van amoxicilline met 
clavulaanzuur 8/8 mg/l, en van meropenem 2/2.5 mg/l. De uitkomsten van deze studie 
suggereren dat er nog mogelijkheden zijn deze medicijnen, of een structuuranaloog, te 
herpositioneren als antituberculose medicatie. Bovendien vraagt dit om een herwaardering 
van andere medicijnklassen als potentiële antituberculose medicijnen.
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Introduction
Drug susceptibility testing (DST) is a prerequisite for reversing the global threat of multidrug-
resistant and extensively drug-resistant tuberculosis. In this thesis we looked at the diagnostic 
accuracy and performance of different (molecular) DST algorithms. A subsequent task would 
be to align these DST algorithms with next-generation treatment regimens.1 But which drugs 
are components of these next-generation treatment regimens? Ideally, they should be oral 
drugs that are effective against susceptible and drug-resistant M. tuberculosis and that have 
minimal interaction with antiretrovirals.2 A regimen consisting of PA-824 (pretonamid), 
moxifloxacin and pyrazinamide (PaMZ) is the first of such a novel regimen undergoing 
clinical testing in phase III. In a 14-day EBA study, this regimen killed mycobacteria as fast 
as the current first-line treatment regimen.3 Results of a 8-week phase II trial are expected 
to be published soon (http://www.tballiance.org/portfolio/trial/nc002).4 A phase III trial 
will start in 2015 (the STAND trial). For an accurate assessment of the impact of these next-
generation treatment regimens, in particular the PaMZ regimen, proper data on pyrazinamide 
and fluoroquinolone resistance is highly needed. Currently, surveillance of pyrazinamide 
resistance is lacking and data on fluoroquinolone resistance is collected in a minority of 
patients only.1
Detecting pyrazinamide resistance
There is increasing evidence that pyrazinamide plays a predominant role in the sputum 
conversion and sterilizing activity of the current first-line antituberculosis treatment regimen.5 
This is because pyrazinamide works better in the interaction with other drugs than it does 
as an isolated component.5 It is this synergistic potential that makes this drug appealing as a 
component in next-generation regimens. For instance, it has been shown that pyrazinamide 
potentiates the activity of important next-generation drugs such as fluoroquinolones and 
bedaquiline.6,7
A recent meta-analysis has indeed shown that susceptibility to pyrazinamide is associated 
with treatment success in MDR-TB treatment.8 Drug susceptibility testing to pyrazinamide is 
therefore important to perform. Though the breakpoint concentration has traditionally been 
set at 100 mg/l, recent pharmacokinetic/-dynamic studies based on pyrazinamide AUC/MIC 
data have suggested that 50 mg/l might be a more clinically relevant susceptibility breakpoint 
predictive for treatment success.9,10 
Drug susceptibility testing to pyrazinamide poses a lot of challenges. False-resistant results 
are frequently seen due to large inoculum sizes causing inactivation of the pyrazinamidase 
enzyme. We have shown that false-resistance may be a problem in up to 68% of samples 
using the MGIT 960 system.11 This means that a first resistant result from the MGIT 960 
system must be interpreted with caution. This has important consequences for the DST to 
pyrazinamide because the MGIT 960 may well be the future gold standard. Some authors 
have therefore proposed to use reduced inoculums size.12 We propose to increase reliability by 
performing a pncA mutation analysis in each resistant MGIT 960 result. We have shown that 
pyrazinamide resistance can reliably be detected in this way (chapter 3). The proposed flow 
diagram may therefore help standardize pyrazinamide resistance testing. 
In high-burden MDR-TB settings a molecular approach would likely be more appropriate to 
accelerate DST. Recent WHO guidelines have recommended that the Xpert® MTB/RIF must 
be used as the initial diagnostic test in adults suspected of having MDR-TB in high-burden 
settings.13 We have shown that in the case of a rpoB mutation a pncA mutation analysis should 
follow and that a pncA mutation indicates a pyrazinamide-resistant MDR M. tuberculosis.14 
Such a strategy, when performed on direct sputum samples, may give accurate results within 
days.15 It could help to stratify MDR-TB treatment according to pyrazinamide susceptibility 
rapidly and accurately,16 for instance in clinical studies evaluating next-generation treatments 
such as the next PaMZ phase III trial (STAND trial).17 
The drawback of performing an pncA mutation analysis is the wide spread of resistance-
determining mutations along the 561bp long pncA gene, making simple molecular DST 
technologies such as line probe assays difficult to design. Moreover, not every pncA mutation 
is strongly associated with phenotypic resistance.18,19 A database with all resistance-
determining mutations, such as recently published, may aid clinical decision making.19 An 
alternative strategy could be to detect the wild type pncA gene as a correlate for pyrazinamide 
susceptibility.1 Likewise, this strategy will depend on the proportion of pyrazinamide resistant 
M. tuberculosis strains with a wild type pncA gene, which could be as high as 15%.19 Other 
mechanisms, such as inhibiting trans-translation and interfering with the pantothenate 
synthesis, might be responsible for inducing pyrazinamide resistance in these isolates. The 
value of molecular markers for these pathways, such as rpsA mutations and panD mutations, 
remains to be determined (Chapter 4).
Detecting fluoroquinolone resistance
Detecting fluoroquinolone resistance would be another important DST strategy to focus 
on. Fluoroquinolones are important second-line drugs in the MDR-TB treatment20 and will 
probably be a component of next-generation treatment regimens as well. Line-probe assays, 
such as the MTBDRsl assay, can be used to detect fluoroquinolone resistance.21 We have shown 
that the MTBDRsl assay may indeed aid in the diagnosis of fluoroquinolone and amikacin 
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resistance in MDR M. tuberculosis isolates (chapter 7). Results from this thesis suggest for 
instance that a gyrA mutation would have a sensitivity and specificity for detecting an XDR 
M. tuberculosis 100% and 97% (chapter 7), which might be cost-effective in high-burden, low-
income settings.22 That’s why we would propose to include the MTBDRsl assay –together with 
pncA mutation analysis- in every isolate with a rpoB mutation to guide treatment initiation.
At present, the WHO does not recommend molecular assays for any second-line drug owing 
to a moderate sensitivity and a subsequently lower negative predictive value.23 Sensitivity 
of the MTBDRsl assay for detecting fluoroquinolone resistance is approximately 89% in 
recent meta-analyses.24,25 It will probably not exceed 90% since 10-40% of fluoroquinolone-
resistant M. tuberculosis strains do not carry target mutations (in codons 90, 91 and 94 of the 
gyrA gene) detected by the MTBDRsl assay.26,27 Other proposed resistance mechanisms are 
mutations outside the quinolone resistance-determining region of the gyrA gene, mutations 
in the gyrB gene, mutations in other genes such as the parC and parE genes, or efflux pump 
mechanisms.27,28 
Notwithstanding this limitation of the MTBDRsl assay, clinicians should not solely focus 
on sensitivity and specificity to appreciate the performance of this test, but should also 
take into account the prevalence of fluoroquinolone resistance.29 Based on a prevalence of 
fluoroquinolone resistance of 20% in MDR-TB samples, found in surveillance of the WHO 
European Region,30 positive and negative predictive value of a gyrA mutation would be 
92% and 97%.29 This means that this test could be safely used for detecting and excluding 
fluoroquinolone resistance in MDR-TB patients in the WHO European region. Only when the 
prevalence exceeds 30%, will the negative predictive value drop below 95%. 
DsT to novel antituberculosis drugs
There are currently several new drug classes that are beyond phase I assessment, such as 
diarylquinolines (bedaquiline), nitroimidazoles (delamanid, pretonamid), oxazolidinones 
(sutezolid, AZD5847), and ethylenediamines (SQ-109).2 Bedaquiline and delamanid are the 
only new drugs that have passed EMA and FDA approval. Rapid DST to these two drugs 
will be a challenge however. DST in the MGIT 960 system is not feasible at the moment for 
both drugs owing to technical restraints (bedaquiline attaches to the MGIT tube and various 
other plastics) and restrictions imposed by the manufacturer in the case of delamanid. As 
a result, DST can only be performed via the slower agar dilution method in few selected 
reference laboratories. There is thus a need to develop faster phenotypic DST platforms for 
both these drugs since they have already been introduced in clinical care. Though resistance-
determining mutations for bedaquiline and delamanid have been identified, it is not expected 
that molecular DST will provide an alternative method for these drugs in the near future; 
the majority of bedaquiline resistant isolates do not carry mutation in the atpE gene31 and the 
majority mutations in the ddn gene are not associated with resistance to nitroimidazoles.32
Besides the development of these new antituberculosis drugs, we have highlighted the 
potential of existing drug as repurposed antituberculosis drugs. We tested a variety of drugs, 
from phenothiazines (chapter 8) to established antimicrobial agents (chapter 9), and showed 
that they all had more or less antimycobacterial activity. It illustrates that we are currently not 
using all potential drug classes in the fight against tuberculosis and this calls for a appraisal of 
other approved (antimicrobial) drugs as potential antituberculosis drugs.
aligning DsT with treatment regimens
In general, DST can be deployed as case-detection assays such as the Xpert MTB/RIF assay 
or as reflex testing after the diagnosis of TB has been made, such as phenotypic DST to 
second-line drugs. At present, a case-detection strategy using molecular DST (Xpert MTB/
RIF) has been prioritized to diagnose MDR-TB in high-burden settings.33 The recent WHO 
policy update from April 2013 has recommended that the Xpert MTB/RIF should replace 
conventional microscopy, culture and DST as the initial diagnostic test in adults suspected of 
having MDR-TB in high-burden settings.33 
There are two important considerations regarding the deployment of such rapid molecular 
DST platforms. The first factor is the health care level implementing the DST algorithm. 
Preferably, case-detection tests should be simple diagnostic tools so they can be used at 
peripheral levels of the health care system. The Xpert MTB/RIF is an example of such a test. 
Such a peripheral focus does not necessitate setting-up an extensive sample transport and 
allows for a rapid turn-around-time so doctors can actually act on DST results immediately 
before transmission of drug-resistant isolates occur.1 Reflex testing is likely more appropriate 
in centralised laboratories that can handle more complex platforms. It requires setting up rapid 
and reliable sample transport and necessitates more patient visits with potential lost to follow-
ups and treatment delays.1 
The second important factor to consider when deciding on diagnostic algorithms is the 
prevailing drug resistance level. In high-burden countries there is good evidence that 
molecular DST as a case-detection strategy for MDR-TB is cost effective, reduces time-
to-diagnosis and treatment initiation.22,33,34 Contrarily, the advantage of such a strategy is 
equivocal in low-burden countries such as the Netherlands.35 Though it is estimated that a 
case-detection strategy for MDR-TB would be cost-effective if prevalence of MDR-TB among 
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smear-positive TB cases is as low as 2%, a moderate to high sensitivity of the molecular DST 
is assumed in such cost-effectiveness studies.36 In low-burden, high resource countries this 
might not the case owing to a high percentage of smear-negative TB cases; sensitivity of 
detecting TB in smear-negative, culture positive TB may be as low as 46% in low-burden 
settings, thereby limiting the applicability of such a test as a screening assay.35 Another concern 
is the limited positive predictive value for MDR-TB in these low-burden countries. It has been 
estimated that positive predictive value diminishes to less than 70% in countries with MDR-
TB prevalence lower than 5%.33 In our sample positive predictive value was higher (80%), 
probably because we used indirect DST in M. tuberculosis cultures from the Netherlands. 
The positive predictive value could be improved by a better risk assessment of the patient. 
However, we showed that common risk factors such as previous treatment, age and 
foreign-born were insufficient to increase predictive value (chapter 7). We would therefore 
argue against a case-detection strategy in the Netherlands. Rather, since there a rapid and 
reliable sample transport in our country, we would recommend reflex testing in centralised 
laboratories. 
The development of DST should not be delayed. Implementing next-generation treatment 
regimens without any back-up surveillance strategy will eventually amplify drug resistance 
and will sacrifice every drug development made so far. The resurgence of MDR-TB cases in 
the New York City outbreak and the high fatality rates in XDR-TB cases in South Africa are a 
vivid reminder of the dangers of relaxing DST development. Nonetheless, balancing between 
this risk of emerging drug resistance and the unabated necessity to provide effective MDR-TB 
treatment as soon as possible is a challenge. It requires political courage and commitment.37 All 
in all, the costs of averting this global threat are huge, but the price of failure will be immense.38
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specialisten Desiree, Nicolle en Nicole, de verpleegkundigen van afdeling C4 en van de 
endoscopieafdeling, die allen niet mogen ontbreken in dit dankwoord.
Het combineren van onderzoek met je opleiding is een uitdaging. De steun van mijn collega’s 
tijdens de opleiding is voor mij essentieel geweest. Herwin, Pepijn, Saar, Marielle, Giny, Hans, 
Wai-Yee, Daan, Roline, Jelle, Ruth, Sandra, Evelien, Freek en Jeroen: van de maandelijkse 
frietavonden voor het longstation, tot het dagelijkse (broodnodige) kopje koffie in de ochtend, 
we hebben als opleidingsgroep de kunst verstaan om van elke dag een feestje te maken. 
Bedankt! 
Professor Theo Thien, al vanaf mijn studietijd bent u voor mij de vraagbaak voor al mijn 
vragen over studeren, werk, onderzoek en de ondoorgrondelijke wegen van de Academie. 
Bedankt voor uw luisterend oor en heldere adviezen. 
Mijn familie en vrienden, jullie zijn onmisbaar voor een gelukkig leven. Pap, mam, het is 
een drukke tijd geweest. Zonder jullie steun en liefde was ik niet geworden wie ik nu ben. 
Maarten: onze vriendschap groeit en bloeit nu al meer dan 30 jaar. Bedankt dat je er al die tijd 
voor mij bent geweest. “Tantes” Liesbeth en Bregje: mijn gezin zou niet hetzelfde zijn zonder 
jullie steun. Bedankt voor al het spiegelen. Gerben en Wouter: we hebben samen de opleiding 
gedaan, we zijn alle drie vader geworden, en we werken nu samen als longarts. Wat is het fijn 
dat we collega’s en vrienden zijn! Dennis en Jeroen: van Dordrecht tot IJsland van zangles 
tot wijnavonden, onze vriendschap maakt mijn leven wat luchtiger. Buurtjes van SoevSoev: 
wat ben ik blij dat onze gezinnen de straat verlevendigen. Alexander, Barbara, Joanneke, 
Annemiek, Onno en alle anderen: Tijd voor een feestje!! 
Hester en Arjan, wat is het bijzonder om onze gezinnen zo hecht samen te zien opgroeien. 
Laten we nog jaren met z’n allen op vakantie gaan! Wout en Arjan, de gedachte dat jullie naast 
mij zullen staan tijdens de promotieplechtigheid maakt mij blij en gelukkig. De vriendschap 
met jullie vormt een wezenlijk onderdeel van mijn leven. 
Lieve Floortje, Isa, en Roos, wat kan ik genieten van jullie knuffelarmen, wat ben ik toch 
gelukkig als ik jullie zelfgeschreven briefjes vind op mijn hoofdkussen en wat is het toch 
heerlijk om jullie te zien opgroeien als mooie, lieve, zelfstandige meiden. Ik ben dankbaar voor 
elke dag die we samen zijn. 
Lieve Ieke, als jij lacht, gaat de zon schijnen. Ik heb je lief, voor altijd.
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